



دانشگاه علوم پزشکی  
و خدمات بهداشتی درمانی کرمان

## دانشکده بهداشت

پایان نامه مقطع دکترای تخصصی (Ph.D) رشته اپیدمیولوژی

عنوان  
تحلیل نظام فارماکوویژیلانس ایران

توسط  
ملاحت خلیلی

اساتید راهنما  
دکتر علی اکبر حقدوست | دکتر حمید شریفی

اساتید مشاور  
دکتر بیتا مسگریور | دکتر مهرناز خیراندیش

سال تحصیلی (اسفند ۱۳۹۹)

شماره پایان نامه: (۱۰/۸/۱/۷)



KERMAN UNIVERSITY  
OF MEDICAL SCIENCES

**Faculty of Public Health**

In Partial Fulfillment of the Requierments for the Degree of Doctor of Philosophy

Title

**Evaluation of Pharmacovigilance System in Iran**

by

**Malahat Khalili**

Supervisors

**Dr. Ali Akbar Haghdoost | Dr. Hamid Sharifi**

Advisors

**Dr. Bita Mesgarpour | Dr. Mehrnaz Kheirandish**

**Thesis No: (10/8/1/7)**

**Date (March, 2021)**

## چکیده

**مقدمه و اهداف:** فارماکوویژیلاانس به عنوان فرآیند شناسایی و پاسخ به موضوعات ایمنی دارو تعریف شده است. ارزیابی نظام فارماکوویژیلاانس به سیاست‌گذاران در شناسایی کمبودهای آن کمک نموده و می‌تواند اقدامات لازم برای اصلاح و بهبود عملکرد نظام فارماکوویژیلاانس را معرفی نماید. از این رو در این مطالعه حاضر سعی گردید ابعاد مختلف نظام فارماکوویژیلاانس در کشور ارزیابی شود.

**روش‌ها:** این پژوهش در چند بخش انجام شد؛ در مطالعه‌ای آینده‌نگر در دو بیمارستان در شهرهای رشت و کرمان بروز عوارض ناخواسته دارویی (ADR) برآورد شد. روند گزارش‌های ADR در بازه زمانی ۱۹ ساله بررسی و کم‌گزارش‌دهی با سه روش مطالعه آینده‌نگر، بررسی متون و طبقه‌بندی کشور تخمین زده شد. وضعیت فارماکوویژیلاانس در ایران با استفاده از شاخص‌های سازمان جهانی بهداشت در چهار سطح ساختار، فرآیند، تأثیر و در برنامه‌های بهداشت عمومی ارزیابی شد. دو پژوهش کیفی به صورت مصاحبه نیمه‌ساختار یافته با کادر درمان و خبرگان برای تبیین درک کادر درمان از نظام فارماکوویژیلاانس، شناسایی موانع گزارش‌دهی ADR و تبیین وضعیت و ویژگی‌های نظام فارماکوویژیلاانس کشور اجرا گردید. یک مطالعه مرور دامنه (scoping review) برای شناسایی مداخلات ارتقادهنده گزارش‌دهی بر اساس چارچوب روش‌شناختی آرکسی انجام گرفت. در نهایت با استفاده از تحلیل SWOT (قوت‌ها، ضعف‌ها، فرصت‌ها و تهدیدها) راهبردهایی برای ارتقا نظام فارماکوویژیلاانس ارائه گردید.

**یافته‌ها:** بروز ADR ۸۴۴/۸ در صد هزار بستری (۱۰۱۳/۲-۶۹۷/۹ CI: ۹۵%) برآورد شد. روند گزارش‌دهی در سال‌های ۱۳۷۸ تا ۱۳۹۶ صعودی و میانه برآوردهای کم‌گزارش‌دهی در ایران ۷۶ در صد بود. ارزیابی برنامه فارماکوویژیلاانس نشان داد که ایمنی داروها توسط مرکز ADR مورد پایش قرار می‌گیرد و این مرکز پرسنل آموزش دیده، بودجه و سیاست ملی برای انجام فعالیت‌های فارماکوویژیلاانس دارا می‌باشد. در سال ۱۳۹۶ تعداد گزارش‌های ADR ۱۵ در صد هزار نفر جمعیت بود. ارزیابی علیتی، شناسایی سیگنال و اقدامات نظارتی در این برنامه انجام می‌شود و شرکت‌های دارویی ملزم به انجام فعالیت‌های فارماکوویژیلاانس هستند. تعداد بستری‌ها و مرگ‌های بیمارستانی ناشی از داروها و وضعیت فعالیت‌های فارماکوویژیلاانس در برنامه‌های

بهداشت عمومی قابل بررسی نبود. هزینه‌ها و مدت زمان بستری بیمارستانی مرتبط با دارو نسبتاً زیاد بود. دانش و آگاهی کادر درمان در زمینه شناسایی و گزارش‌دهی ADR مطلوب نبود. ضعف در فرآیند گزارش‌دهی، عدم آگاهی، محیط کاری و خصوصیات فردی از موانع اصلی در گزارش‌دهی ADR بودند. از دیدگاه خبرگان نواقص گسترده‌ای در ساختار، زیرساخت‌ها و امکانات، فرآیند گزارش‌دهی، همکاری‌های بین‌بخشی، جلب مشارکت کادر درمان و شرکت‌های دارویی، نظارت و پیگیری، ارزیابی و تحلیل گزارش‌ها و عملکرد وجود دارد. استراتژی‌هایی برای ارتقا ساختار برنامه، فرآیند گزارش‌دهی و همچنین بهبود اثرات و عملکرد برنامه فارماکوویژیلاانس پیشنهاد شدند. ضمن اینکه مداخلاتی همچون آموزش، پایش فعال و ثبت کامپیوتری گزارش‌ها و مشوق‌های مالی می‌توانند در ارتقای گزارش‌دهی ADR مؤثر باشند.

**بحث و نتیجه‌گیری:** این مطالعه نیاز اساسی برای تقویت نظام فارماکوویژیلاانس ایران را نشان داده است. نظام فارماکوویژیلاانس می‌تواند با تسهیل فرآیند گزارش‌دهی، آموزش و اطلاع‌رسانی، افزایش همکاری‌های بین‌بخشی و جمع‌آوری داده‌های ایمنی از منابع مختلف نسبت به وضعیت داروها و عوامل خطر مطلع شود و اقدامات لازم و به موقع برای حفظ ایمنی بیماران و کاهش خطر را انجام دهد. مشارکت کادر بهداشتی و درمانی، شرکت‌های دارویی، دانشگاه‌های علوم پزشکی، پژوهشگران و عموم مردم در گزارش‌دهی و فعالیت‌های فارماکوویژیلاانس به سلامت عمومی و بهبود ایمنی در مصرف داروها کمک خواهد نمود.

**واژگان کلیدی:** فارماکوویژیلاانس، نظام‌های گزارش‌دهی عوارض ناخواسته دارویی، عوارض جانبی و واکنش‌های ناخواسته مرتبط با دارو، گزارش‌دهی داوطلبانه رخداد ایمنی بیمار

## **Abstract**

**Introduction and Objectives:** Pharmacovigilance has been defined as the process of identifying and responding to drug safety issues. Evaluating the pharmacovigilance system helps policymakers identify its deficiencies and recommends measures to remedy and improve the pharmacovigilance system's function. Therefore, different aspects of the Iranian pharmacovigilance system were evaluated in the present study.

**Methods:** This study was conducted in several parts; The incidence of adverse drug reaction (ADR) was estimated in prospective studies in two hospitals in Rasht and Kerman. The ADR reports trend was assessed over 19 years, and three methods, i.e., prospective study, literature review, and country's stratification, estimated its underreporting. The status of pharmacovigilance in Iran was evaluated using WHO pharmacovigilance indicators in four categories: structure, processes, outcomes, and pharmacovigilance in the Iranian public health programs. Two qualitative studies were carried out. Semi-structured interviews were conducted with healthcare professionals and experts to understand their view of the pharmacovigilance system and identify the barriers to ADR reporting and explain the Iranian pharmacovigilance system's status. According to Arksey and O'Malley's methodological framework, a scoping review was conducted to identify interventions that improve ADR reporting. Finally, strategies to strengthen the pharmacovigilance system were presented using SWOT (strengths, weaknesses, opportunities, and threats) analysis.

**Results:** ADR incidence was 844.8 per 100 000 admissions (95% CI: 697.9-1013.2). The ADR reporting trend increased from 1999 to 2017, and the median of estimated percentages of

underreporting was 76.0%. The pharmacovigilance program's evaluation also showed that drug safety is monitored by the Iran ADR Center and has a national policy, trained staff, and a statutory budget. In 2017, the number of ADR reports was 15.0 per 100 000 population. Causality assessment, signal detection, and regulatory actions are performed in this program, and pharmaceutical companies are required to administrate pharmacovigilance activities. Moreover, the number of hospital admissions and deaths due to drug reactions and the status of pharmacovigilance activities in public health programs could not be assessed. The length and cost of hospitalization related to drugs were relatively high. The knowledge and awareness of healthcare professionals about ADR identification and reporting were not desirable. Weakness in the reporting process, lack of knowledge, work environment status, and personal characteristics were the main obstacles in ADR reporting. From the experts' point of view, there are widespread shortcomings in the structure, infrastructure, facilities, reporting process, cross-sectoral cooperation, the involvement of healthcare professionals and pharmaceutical companies, monitoring and follow-up, evaluation and analysis of reports and performance. Strategies were suggested to improve the program's structure and reporting process and promote the pharmacovigilance program's impact and outcome. Besides, interventions such as education, active monitoring, and computerized reporting registration and financial incentives could help amend ADR reporting.

**Conclusion:** This study has shown a crucial need to strengthen the pharmacovigilance system in Iran. The pharmacovigilance system can be informed about the status of drugs and risk factors in society by facilitating the reporting process, training and noticing, increasing inter-sectoral collaborations,

and collecting safety data from various sources. It should take necessary and timely measures to sustain patient's safety and risk minimization. Participation of healthcare professionals, pharmaceutical companies, medical sciences universities, researchers, and the general public in reporting and pharmacovigilance activities will contribute to public health and improve drug usage safety.

**Keyword:** Pharmacovigilance, Adverse Drug Reaction Reporting Systems, Drug-Related Side Effects and Adverse Reactions, Voluntary Patient Safety Event Reporting

## فهرست مندرجات

ط	فهرست جداول	.....
ی	فهرست نمودارها	.....
ک	فهرست شکل‌ها	.....
ل	فهرست پیوست‌ها	.....
م	فهرست کوتاه نوشته‌ها	.....
	چکیده	.....

### فصل اول: مقدمه و اهداف

۲	۱-۱ مقدمه	.....
۳	۱-۲ بیان مسأله	.....
۱۰	۱-۳ اهداف	.....
۱۰	۱-۳-۱ اهداف کلی	.....
۱۰	۱-۳-۲ اهداف جزئی	.....
۱۰	۱-۳-۳ اهداف کاربردی	.....
۱۱	۱-۴ سؤالات پژوهش	.....
۱۲	۱-۵ تعاریف واژه‌ها	.....

### فصل دوم: بررسی متون

۱۷	۱-۲ مقدمه	.....
۱۹	۲-۲ سابقه پژوهش‌های فارماکوویزیلانس در کشورهای در حال توسعه	.....
۲۵	۲-۳ سابقه پژوهش‌های فارماکوویزیلانس در کشورهای توسعه‌یافته	.....
۲۷	۲-۴ سابقه پژوهش‌های فارماکوویزیلانس در ایران	.....

### فصل سوم: تعیین بروز عوارض ناخواسته دارویی و عوامل مؤثر بر آن

۳۱	۳-۱ روش تحقیق	.....
۳۱	۳-۱-۱ روش مطالعه و محل انجام آن	.....
۳۲	۳-۱-۲ جمع‌آوری داده‌ها	.....
۳۴	۳-۱-۳ اخلاق	.....
۳۴	۳-۱-۴ تحلیل آماری	.....
۳۷	۳-۲ یافته‌ها	.....
۳۷	۳-۲-۱ نتایج توصیفی	.....
۳۷	۳-۲-۲ عوامل مؤثر بر بروز ADR	.....
۴۲	۳-۲-۳ تظاهرات بالینی عوارض دارویی شناسایی شده	.....
۴۲	۳-۲-۴ نوع داروهای منجر به عوارض ناخواسته دارویی	.....



- ۴۴..... ۳-۲-۵ برآورد هزینه‌های مرتبط با بروز عوارض ناخواسته دارویی
- ۴۵..... ۳-۲-۶ برآورد طول مدت بستری به دنبال بروز عوارض ناخواسته دارویی
- ۴۶..... ۳-۳ بحث و نتیجه‌گیری

**فصل چهارم: تحلیل توصیفی گزارش‌های ADR مرکز فارماکوویژیلاانس و برآورد کم گزارش‌دهی ADR**

- ۵۳..... ۴-۱ روش تحقیق
- ۵۴..... ۴-۱-۱ توصیف وضعیت گزارش‌دهی ADR
- ۵۴..... ۴-۱-۲ برآورد کم گزارش ADR
- ۵۸..... ۴-۱-۳ Cross-Validation درصد‌های کم گزارش‌دهی برآورد شده
- ۵۹..... ۴-۱-۴ تحلیل آماری
- ۶۱..... ۴-۲ یافته‌ها
- ۶۱..... ۴-۲-۱ تحلیل توصیفی گزارش‌دهی
- ۶۱..... ۴-۲-۲ روند گزارش‌دهی ADR
- ۶۲..... ۴-۲-۳ توزیع جغرافیایی گزارش‌دهی ADR
- ۶۴..... ۴-۲-۴ برآورد کم گزارش‌دهی ADR بر اساس نتایج مطالعه آینده‌نگر
- ۶۴..... ۴-۲-۵ برآورد کم گزارش‌دهی ADR بر اساس بررسی متون
- ۶۷..... ۴-۲-۶ برآورد کم گزارش‌دهی ADR بر اساس طبقه‌بندی کشور
- ۶۸..... ۴-۲-۷ Cross-Validation برآوردهای کم گزارش‌دهی
- ۷۱..... ۴-۳ بحث و نتیجه‌گیری

**فصل پنجم: تحلیل نظام فارماکوویژیلاانس ایران با شاخص‌های WHO**

- ۷۸..... ۵-۱ روش تحقیق
- ۷۸..... ۵-۱-۱ روش مطالعه
- ۷۹..... ۵-۱-۲ معرفی شاخص‌های اصلی فارماکوویژیلاانس WHO
- ۷۹..... ۵-۱-۳ جمع‌آوری داده‌ها
- ۸۰..... ۵-۱-۴ تحلیل داده‌ها
- ۸۲..... ۵-۲ یافته‌ها
- ۸۲..... ۵-۲-۱ شاخص‌های ساختاری
- ۸۴..... ۵-۲-۲ شاخص‌های فرآیند
- ۸۴..... ۵-۲-۳ شاخص‌های پیامد/تأثیر
- ۸۷..... ۵-۲-۴ شاخص‌های فارماکوویژیلاانس برای برنامه‌های بهداشت عمومی
- ۸۹..... ۵-۳ بحث و نتیجه‌گیری

**فصل ششم: تبیین درک کادر درمان از نظام فارماکوویژیلاانس و شناسایی موانع موجود در گزارش‌دهی ADR**

- ۹۸..... ۶-۱ روش تحقیق
- ۹۸..... ۶-۱-۱ روش و محل انجام مطالعه

۹۹.....	۶-۱-۲ جامعه مورد مطالعه و نمونه‌گیری
۹۹.....	۶-۱-۳ جمع‌آوری داده‌ها و انجام مصاحبه‌ها
۱۰۰.....	۶-۱-۴ تحلیل داده‌ها
۱۰۲.....	۶-۲ یافته‌ها
۱۲۱.....	۶-۳ بحث و نتیجه‌گیری
<b>فصل هفتم: تبیین ویژگی‌های نظام فارماکوویژیلانس کارآمد و شناسایی وضعیت برنامه فارماکوویژیلانس ایران از دیدگاه خبرگان</b>	

۱۲۶.....	۷-۱ روش تحقیق
۱۲۶.....	۷-۱-۱ روش مطالعه
۱۲۶.....	۷-۱-۲ جامعه مورد مطالعه و نمونه‌گیری
۱۲۷.....	۷-۱-۳ جمع‌آوری داده‌ها و انجام مصاحبه‌ها
۱۲۸.....	۷-۱-۴ تحلیل داده‌ها
۱۳۰.....	۷-۲ یافته‌ها
۱۷۱.....	۷-۳ بحث و نتیجه‌گیری

**فصل هشتم: مرور دامنه‌ای برای شناسایی مداخلات ارتقادهنده گزارش‌دهی ADR**

۱۸۰.....	۸-۱ روش تحقیق
۱۸۰.....	۸-۱-۱ مرحله ۱: شناسایی سوال پژوهش
۱۸۱.....	۸-۱-۲ مرحله ۲: شناسایی مطالعات مرتبط
۱۸۱.....	۸-۱-۳ مرحله ۳: انتخاب مطالعه
۱۸۲.....	۸-۱-۴ مرحله ۴: ارائه و چارت کردن داده‌ها
۱۸۲.....	۸-۱-۵ مرحله ۵: جمع‌بندی، خلاصه‌سازی و گزارش یافته‌ها
۱۸۳.....	۸-۱-۶ مرحله ۶: مشاوره گرفتن
۱۸۴.....	۸-۲ یافته‌ها
۱۸۴.....	۸-۲-۱ مشخصات مقالات وارد شده در مطالعه
۱۸۸.....	۸-۲-۲ دسته‌های اصلی مداخلات برای ارتقا گزارش‌دهی ADR
۱۹۵.....	۸-۲-۳ مشاوره گرفتن
۱۹۶.....	۸-۳ بحث و نتیجه‌گیری

**فصل نهم: تحلیل SWOT نظام فارماکوویژیلانس ایران**

۲۰۲.....	۹-۱ روش تحقیق
۲۰۴.....	۹-۲ یافته‌ها
۲۰۴.....	۹-۲-۱ ماتریس تحلیل SWOT
۲۱۰.....	۹-۲-۲ تدوین استراتژی بر اساس تحلیل SWOT
۲۱۲.....	۹-۳ بحث و نتیجه‌گیری

فصل دهم: نتیجه‌گیری

۲۲۵.....منابع

۲۶۱.....پیوست‌ها

## فهرست جداول

- جدول ۱-۳: بررسی عوامل مؤثر بروز عوارض ناخواسته دارویی (ADR) در بیماران بر اساس رگرسیون پواسن تک متغیره ..... ۳۸
- جدول ۲-۳: بررسی عوامل مؤثر بروز عوارض ناخواسته دارویی (ADR) در بیماران بر اساس رگرسیون پواسن چند متغیره ..... ۴۱
- جدول ۳-۳: برآورد هزینه‌های بستری در بیمارستان‌های رازی و افضل‌پور ..... ۴۵
- جدول ۳-۴: برآورد طول مدت بستری در بیمارستان‌های رازی و افضل‌پور ..... ۴۵
- جدول ۱-۴: برآورد درصد کم‌گزارش‌دهی عوارض ناخواسته دارویی (ADR) در ایران بر اساس دو مطالعه آینده‌نگر ..... ۶۵
- جدول ۲-۴: برآورد درصد کم‌گزارش‌دهی عوارض ناخواسته دارویی در ایران بر اساس بررسی متون ..... ۶۶
- جدول ۳-۴: برآورد کم‌گزارش‌دهی عوارض ناخواسته دارویی در ایران بر اساس روش طبقه‌بندی کشور در سال ۱۳۹۶ ..... ۶۷
- جدول ۱-۵: تحلیل برنامه فارماکوویژیلاانس با استفاده از شاخص‌های ساختاری WHO ..... ۸۲
- جدول ۲-۵: تحلیل برنامه فارماکوویژیلاانس ایران با استفاده از شاخص‌های فرآیند و پیامد WHO ..... ۸۵
- جدول ۳-۵: تحلیل وضعیت اجرای فارماکوویژیلاانس در برنامه‌های بهداشت عمومی ایران با استفاده از شاخص‌های WHO ..... ۸۸
- جدول ۱-۶: مشخصات دموگرافیک افراد شرکت‌کننده در مصاحبه ..... ۱۰۲
- جدول ۲-۶: تحلیل تماتیک داده‌های حاصل از مصاحبه با ۲۲ نفر از کادر درمان در کشور ..... ۱۱۳
- جدول ۱-۷: مشخصات شرکت‌کنندگان در مصاحبه ..... ۱۳۰
- جدول ۲-۷: تحلیل تماتیک داده‌های حاصل از مصاحبه با ۱۶ نفر از خبرگان در حیطه فارماکوویژیلاانس ..... ۱۵۹
- جدول ۱-۸: انواع مداخلات آموزشی در مطالعات وارد شده در مرور حیطه ..... ۱۸۹
- جدول ۲-۸: ماتریس شماتیک تأثیر مداخلات بر بهبود گزارش‌دهی ADR ها ..... ۱۹۱
- جدول ۱-۹: ماتریس تحلیل SWOT نظام فارماکوویژیلاانس ایران ..... ۲۰۸
- جدول ۲-۹: استراتژی‌ها برای ارتقا نظام فارماکوویژیلاانس بر اساس تحلیل SWOT ..... ۲۰۹

## فهرست نمودارها

- نمودار ۱-۳: بروز عوارض ناخواسته دارویی برحسب ارگان درگیر بدن در بیمارستان‌های رازی و افضلی-پور..... ۴۳
- نمودار ۲-۳: دسته‌های دارویی منجر به واکنش‌های ناخواسته دارویی در بیمارستان‌های رازی و افضلی‌پور..... ۴۴
- نمودار ۱-۴: روندهای گزارش‌دهی عوارض ناخواسته دارویی در ۱۰۰۰۰۰ نفر جمعیت طی ۱۹۹۹-۲۰۱۷..... ۶۲
- نمودار ۲-۴: روند تصحیح شده نسبت گزارش‌دهی عوارض ناخواسته دارویی (ADR) در هر ۱۰۰۰۰۰ جمعیت، ۱۹۹۹-۲۰۱۷..... ۷۰
- نمودار ۱-۸: توزیع مطالعات مورد بررسی بر حسب سال و نوع مداخله..... ۱۸۸

## فهرست شکل‌ها

- شکل ۱-۱: فلوجارت مراحل انجام کار ..... ۹
- شکل ۱-۳: فلوجارت اهداف مطالعه آینده‌نگر در دو بیمارستان رازی و افضل‌پور ..... ۳۲
- شکل ۱-۴: توزیع فضایی گزارش‌دهی عوارض ناخواسته دارویی در ۱۰۰۰۰۰ پذیرش بیمارستانی در سال ۱۳۹۶ ..... ۶۳
- شکل ۲-۴: توزیع فضایی گزارش‌دهی عوارض ناخواسته دارویی در ۱۰۰۰۰۰ نفر جمعیت در سال ۱۳۹۶ ..... ۶۳
- شکل ۳-۴: فلوجارت مراحل تصحیح نسبت گزارش‌دهی عوارض ناخواسته دارویی (ADR) ..... ۶۹
- شکل ۱-۵: شاخص‌های اصلی WHO برای فارماکوویژی‌یلانس و منابع داده‌ها برای شاخص‌ها ..... ۸۱
- شکل ۱-۶: ساختار مفهومی برای تبیین درک کادر درمان کشور از نظام فارماکوویژی‌یلانس و شناسایی موانع موجود در گزارش‌دهی عوارض ناخواسته دارویی (ADR) ..... ۱۱۲
- شکل ۱-۷: مدل فرآیند فعالیت‌های فارماکوویژی‌یلانس بر اساس نظر خبرگان ..... ۱۵۷
- شکل ۲-۷: چهار چوب مفهومی الزامات یک نظام فارماکوویژی‌یلانس کارآمد بر اساس نظر خبرگان ..... ۱۵۸
- شکل ۱-۸: فلوجارت مطالعات شناسایی شده برای مرور دامنه ..... ۱۸۵
- شکل ۲-۸: توزیع جغرافیایی مطالعات وارد شده در مرور دامنه ..... ۱۸۶

## فهرست پیوست ها

- پیوست ۱: مشخصات بیمارستان های مورد مطالعه برای بررسی بروز عوارض ناخواسته دارویی ..... ۲۶۲
- پیوست ۲: تظاهرات بالینی عوارض ناخواسته دارویی (ADR) شناسایی شده در مطالعه آینده نگر در دو بیمارستان رازی و افضل پور  
..... ۲۶۳
- پیوست ۳: دسته های دارویی منجر به واکنش های ناخواسته دارویی به تفکیک داروهای عرضه دهنده در بیمارستان های رازی و  
افضل پور..... ۲۶۵
- پیوست ۴: مشخصات دموگرافیک، نظام سلامت و دارویی ایران ..... ۲۶۶
- پیوست ۵: پرسش نامه تحلیل نظام مراقبت دارویی (Pharmacovigilance) در ایران..... ۲۶۷
- پیوست ۶: گویه های تکمیلی در مصاحبه های کیفی با خبرگان ..... ۲۷۳
- پیوست ۷: استراتژی های جستجوی در پایگاه های اطلاعاتی مورد مطالعه ..... ۲۷۵
- پیوست ۸: مشخصات مطالعات وارد شده در مرور دامنه ..... ۲۷۷

1. Alhawassi TM, Krass I, Bajorek BV, Pont LG. A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. *Clin Interv Aging*. 2014;9:2079-86.
2. Qato DM. Current state of pharmacovigilance in the Arab and Eastern Mediterranean region : results of a 2015 survey. *International Journal of Pharmacy Practice*. 2018;26(3):210-21.
3. Linnér L, Eriksson I, Persson M, Wettermark B. Forecasting drug utilization and expenditure: ten years of experience in Stockholm. *BMC Health Services Research*. 2020;20(1):410.
4. Kabore L, Millet P, Fofana S, Berdai D, Adam C, Haramburu F. Pharmacovigilance systems in developing countries : an evaluative case study in Burkina Faso. *Drug Safety*. 2013;36(5):349-58.
5. Moore N, Berdai D, Blin P, Droz C. Pharmacovigilance - The next chapter. *Therapies*. 2019;74(6):557-67.
6. Ofori-Asenso R, Agyeman AA. Irrational Use of Medicines-A Summary of Key Concepts. *Pharmacy (Basel)*. 2016;4(4):35.
7. Moscou K, Kohler JC. Matching safety to access : global actors and pharmacogovernance in Kenya- a case study. *Globalization and Health*. 2017;13(1):20.
8. Nwokike J, Joshi M. *Pharmacovigilance in Rwanda : A Systems Analysis*. Arlington, VA : Management Sciences for Health; 2009.



9. World Health Organization. Minimum requirements for a functional pharmacovigilance system Geneva: WHO; 2010 [cited 2020 31 March]. Available from: <https://apps.who.int/medicinedocs/en/m/abstract/Js23393en./>
10. Nwokike J, Ludeman E, Thumm M. Comparative Analysis of Pharmacovigilance Systems in Five Asian Countries. Arlington, VA : Management Sciences for Health; 2013 .
11. Maigetter K, Pollock AM, Kadam A, Ward K, Weiss MG. Pharmacovigilance in India, Uganda and South Africa with reference to WHO's minimum requirements. International Journal of Health Policy and Management .2015; 4(5):259
12. World Health Organization. WHO pharmacovigilance indicators : a practical manual for the assessment of pharmacovigilance systems Geneva : WHO; 2015 [cited 2020 31 March]. Available from : <https://apps.who.int/medicinedocs/en/m/abstract/Js21970en./>
13. Fang H, Lin X, Zhang J, Hong Z, Sugiyama K, Nozaki T, et al. Multifaceted interventions for improving spontaneous reporting of adverse drug reactions in a general hospital in China. BMC Pharmacology and Toxicology. 2017;18(1):49.
14. Ribeiro-Vaz I, Herdeiro MT, Polónia J, Figueiras A. Strategies to increase the sensitivity of pharmacovigilance in Portugal. Revista de Saúde Pública. 2011;45(1):129-35.
15. Hartholt KA, Van Der Velde N, Looman CW, Panneman MJ, Van Beeck EF, Patka P, et al. Adverse drug reactions related hospital admissions in persons aged 60 years and over, The Netherlands, 1981-2007 : less rapid increase, different drugs. PLOS One. 2010;5(11):e13977.

16. Patel H, Bell D, Molokhia M, Srishanmuganathan J, Patel M, Car J, et al. Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998–2005. *BMC clinical pharmacology*. 2007;7:9.
17. Khalil H, Huang C. Adverse drug reactions in primary care : a scoping review. *BMC Health Services Research*. 2020;20(1):5.
18. Angamo MT, Chalmers L, Curtain CM, Bereznicki LRE. Adverse Drug Reaction Related Hospitalisations in Developed and Developing Countries : A Review of Prevalence and Contributing Factors. *Drug Safety*. 2016;39(9):847–57.
19. Conforti A, Costantini D, Zanetti F, Moretti U, Grezzana M, Leone R. Adverse drug reactions in older patients : an Italian observational prospective hospital study. *Drug, healthcare and patient safety*. 2012;4:75–80.
20. Poudel DR, Acharya P, Ghimire S, Dhital R, Bharati R. Burden of hospitalizations related to adverse drug events in the USA: a retrospective analysis from large inpatient database. *Pharmacoepidemiology and Drug Safety*. 2017;26(6):635–41.
21. Stausberg J, Hasford J. Drug-related admissions and hospital-acquired adverse drug events in Germany : a longitudinal analysis from 2003 to 2007 of ICD-10-coded routine data. *BMC Health Services Research*. 2011;11:134.
22. Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of Adverse Drug Reactions in Europe: A Review of Recent Observational Studies. *Drug Safety*. 2015;38(5):437–53.

23. Bé nard-Laribiè re A, Miremont-Salamé G, Pé rault-Pochat M-C, Noize P, Haramburu F. Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study. *Fundamental & Clinical Pharmacology*. 2015;29(1):106-11.
24. Carrasco-Garrido P, de André s LA, Barrera VH, de Miguel GÁ, Jimé nez-García R. Trends of adverse drug reactions related-hospitalizations in Spain (2001-2006). *BMC Health Services Research*. 2010;10(1):287.
25. Angamo MT, Chalmers L, Curtain CM, Bereznicki LR. Adverse-drug-reaction-related hospitalisations in developed and developing countries: A review of prevalence and contributing factors. *Drug Safety*. 2016;39(9):847-57.
26. Parameswaran Nair N, Chalmers L, Peterson GM, Bereznicki BJ, Castelino RL, Bereznicki LR. Hospitalization in older patients due to adverse drug reactions -the need for a prediction tool. *Clin Interv Aging*. 2016;11 :497-505.
27. Avong YK, Jatau B, Gurumnaan R, Danat N, Okuma J, Usman I, et al. Addressing the under-reporting of adverse drug reactions in public health programs controlling HIV/AIDS, Tuberculosis and Malaria: A prospective cohort study. *PLOS One*. 2018;13(8):e0200810.
28. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *JAMA*. 1998;279(15):1200-5.
29. Patel TK, Patel PB. Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis. *European Journal of Clinical Pharmacology*. 2018;74(6):819-32.
30. Batel Marques F, Penedones A, Mendes D, Alves C. A systematic review of observational studies evaluating costs of adverse drug reactions. *Clinicoecon Outcomes Res*. 2016;8:413-26.

31. World Health Organization. The safety of medicines in public health programmes: pharmacovigilance, an essential tool. 2006.
32. Fornasier G, Francescon S, Leone R, Baldo P. An historical overview over Pharmacovigilance. *International Journal of Clinical Pharmacy*. 2018;40(4):744-7.
33. Edwards IR, Bencheikh RS. Pharmacovigilance is ... Vigilance. *Drug Safety*. 2016;39(4):281-5.
34. Barry A, Olsson S, Minzi O, Bienvenu E, Makonnen E, Kamuhabwa A, et al. Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania. *Drug Safety*. 2020.
35. Organization WH. The importance of pharmacovigilance safety monitoring of medicinal products Geneva: World Health Organization,; 2002.
36. World Health Organization. The importance of pharmacovigilance: safety monitoring of medicinal products. Geneva: World Health Organization; 2002.
37. Olsson S, Pal SN, Dodoo A. Pharmacovigilance in resource-limited countries. *Expert Review of Clinical Pharmacology*. 2015;8(4):449-60.
38. Kim S, Yu YM, You M, Jeong KH, Lee E. A cross-sectional survey of knowledge, attitude, and willingness to engage in spontaneous reporting of adverse drug reactions by Korean consumers. *BMC Public Health*. 2020;20(1):1527.
39. Hoffman KB, Dimbil M, Tatonetti NP, Kyle RF. A pharmacovigilance signaling system based on FDA regulatory action and post-marketing adverse event reports. *Drug Safety*. 2016;39(6):561-75.

40. Chang F, Xi Y, Zhao J, Zhang X, Lu Y. A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. *Journal of evaluation in clinical practice*. 2017;23(6):1316-21.
41. Olsson S, Pal SN, Dodoo A. Pharmacovigilance in resource-limited countries. *Expert review of clinical pharmacology*. 2015;8(4):449-60.
42. World Health Organization. WHO pharmacovigilance indicators : a practical manual for the assessment of pharmacovigilance systems. Geneva; 2015 .
43. Wal P, Wal A, Gupta S, Sharma G, Rai AK. Pharmacovigilance of Herbal Products in India. *Journal of Young Pharmacists : JYP*. 2011;3(3):256-8.
44. Olsson S, Pal SN, Stergachis A, Couper M. Pharmacovigilance activities in 55 low-and middle-income countries. *Drug Safety*. 2010;33(8):689-703.
45. Pirmohamed M, Atuah KN, Dodoo ANO, Winstanley P. Pharmacovigilance in developing countries. *BMJ*. 2007;335(7618):457-62.
46. Elshafie S, Zaghloul I, Roberti AM. Pharmacovigilance in developing countries (part I) : importance and challenges. *International Journal of Clinical Pharmacy*. 2018;40(4):758-63.
47. Hoffmann E, Fouretier A, Vergne C, Bertram D. Pharmacovigilance regulatory requirements in Latin America. *Pharmaceutical Medicine*. 2012;26(3):153-64.
48. Opadeyi AO, Fourrier-Réglat A, Isah AO. Assessment of the state of pharmacovigilance in the South-South zone of Nigeria using WHO pharmacovigilance indicators. *BMC Pharmacology and Toxicology*. 2018;19(1):27.

49. World Health Organization. Minimum requirements for a functional pharmacovigilance system. Geneva: WHO. 2010.
50. Hanafi S, Torkamandi H, Hayatshahi A, Gholami K, Shahmirzadi NA, Javadi MR. An educational intervention to improve nurses' knowledge, attitude, and practice toward reporting of adverse drug reactions. *Iranian Journal of Nursing and Midwifery Research*. 2014;19(1):101-6.
51. Alavijeh MM, Matin BK, Mahboubi M, Jalilian F. Factors related with adverse drug reaction reporting: a cross-sectional study among pharmacists in the West of Iran. *Arvand journal of health and medical sciences*. 2016;1(1):43-9.
52. Peymani P, Tabrizi R, Afifi S, Namazi S, Heydari ST, Shirazi MK, et al. Knowledge, attitude and practice of General Practitioners towards adverse drug reaction reporting in South of Iran, Shiraz (Pharmacoepidemiology report). *International Journal of Risk & Safety in Medicine*. 2016;28:25-31.
53. Vessal G, Mardani Z, Mollai M. Knowledge, attitudes, and perceptions of pharmacists to adverse drug reaction reporting in Iran. *Pharmacy World & Science*. 2009;31(2):183-7.
54. Hamedivafa F, Peiravian F. A survey of knowledge, attitude and practice of nurses towards pharmacovigilance in teaching hospital, Qazvin-Iran. *Research in Pharmaceutical Sciences*. 2012;7(5):863.
55. Namazi S, Borhani-Haghighi A, Karimzadeh I. Adverse Reactions to Antiepileptic Drugs in Epileptic Outpatients: A Cross-Sectional Study in Iran. *Clinical Neuropharmacology*. 2011;34(2):79-83.

56. Pourseyed S, Fattahi F, Pourpak Z, Gholami K, Shariatpanahi SS, Moin A, et al. Adverse drug reactions in patients in an Iranian department of internal medicine. *Pharmacoepidemiology and Drug Safety*. 2009;18(2):104-10.
57. Mohebbi N, Shalviri G, Salarifar M, Salamzadeh J, Gholami K. Adverse drug reactions induced by cardiovascular drugs in cardiovascular care unit patients. *Pharmacoepidemiology and Drug Safety*. 2010;19(9):889-94.
58. Sepahi M, Movahed Z, Heydari H, Shirkhodai M, Shokrollahi M. Surveillance of adverse drug reaction in hospitalized children, a cross sectional study from Qom Province, Iran. *Life Science Journal*. 2013;10(12s):122-5.
59. Baniasadi S, Fahimi F, Shalviri G. Developing an Adverse Drug Reaction Reporting System at a Teaching Hospital. *Basic & Clinical Pharmacology & Toxicology*. 2008;102(4):408-11.
60. Baniasadi S, Habibi M, Haghgoo R, Gamishan MK, Dabaghzadeh F, Farasatinasab M, et al. Increasing the number of adverse drug reactions reporting: the role of clinical pharmacy residents. *Iranian Journal of Pharmaceutical Research: IJPR*. 2014;13(1):291.
61. Baniasadi S, Namdar R, Fahimi F. Development of an adverse drug reaction bulletin in a teaching hospital. *Modern Medicine*. 2009;44(11):333-5.
62. Shalviri G, Valadkhani M, Dinarvand R. Ten years pharmacovigilance activities in Iran. *Iranian Journal of Public Health*. 2009;38(Supple 1).
63. Javidnikoo N, Karimi-Ghavanloo M, Kheirandish M. Report of Adverse Drug Reaction and Medication Error in 2016 and 2017. *Razi Drug Monthly*; 2019.

64. Isfahani ME, Mousavi S, Rakhshan A, Assarian M, Kuti L, Eslami K. Adverse drug reactions : knowledge, attitude and practice of pharmacy students. *Journal of Pharmaceutical Care*. 2013;1(4):145-8.
65. Hanafi S, Torkamandi H, Hayatshahi A, Gholami K, Javadi M. Knowledge, attitudes and practice of nurse regarding adverse drug reaction reporting. *Iranian Journal of Nursing and Midwifery Research*. 2012;17(1):21-5.
66. Afifi S, Maharlouei N, Peymani P, Namazi S, Gharaei AG, Jahani P, et al. Adverse drug reactions reporting : pharmacists' knowledge, attitude and practice in Shiraz, Iran. *International Journal of Risk and Safety in Medicine*. 2014;26(3):139-45.
67. Mirbaha F, Shalviri G, Yazdizadeh B, Gholami K, Majdzadeh R. Perceived barriers to reporting adverse drug events in hospitals : a qualitative study using theoretical domains framework approach. *Implementation Science*. 2015;10(1):110.
68. Kaufman G. Adverse drug reactions : classification, susceptibility and reporting. *Nursing Standard*. 2016;30 (50).
69. Edwards IR, Aronson JK. Adverse drug reactions : definitions, diagnosis, and management. *The lancet*. 2000;356(9237):1255-9.
70. Pourpak Z, Fazlollahi MR, Fattahi F. Understanding adverse drug reactions and drug allergies : principles, diagnosis and treatment aspects. *Recent patents on inflammation & allergy drug discovery*. 2008;2(1):24-46.
71. Saha P. Starting-Up A Pharmacovigilance Network from Scratch : A Brief Plan. *Journal of Pharmaceutical Research*. 2014;4(1):58-66.



72. World Health Organization. The importance of pharmacovigilance. 2002.
73. Anton C, Cox AR, Ferner RE. Improving follow-up rates in spontaneous adverse drug reaction reporting. *Drug Safety*. 2009;32(12):1135-40.
74. Bandekar M, Anwikar S, Kshirsagar N. Quality check of spontaneous adverse drug reaction reporting forms of different countries. *Pharmacoepidemiology and Drug Safety*. 2010;19(11):1181-5.
75. Biagi C, Montanaro N, Buccellato E, Roberto G, Vaccheri A, Motola D. Underreporting in pharmacovigilance : an intervention for Italian GPs (Emilia-Romagna region). *European Journal of Clinical Pharmacology*. 2013;69(2) :237-44.
76. Hazell L, Shakir S. Under-reporting of adverse drug reactions : A systematic review. *Drug Safety*. 2006;29 :385-96.
77. Lopez-Gonzalez E, Herdeiro MT, Piñeiro-Lamas M, Figueiras A. Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial. *Drug Safety*. 2015;38(2):189-96.
78. Varallo FR, Planeta CS, Mastroianni PdC. Effectiveness of pharmacovigilance: multifaceted educational intervention related to the knowledge, skills and attitudes of multidisciplinary hospital staff. *Clinics*. 2017;72(1):51-7.
79. Perumaloo AAP. From evolution to prevention of adverse drug reaction. *International Journal of Pharmacy*. 2015;5(4):1170-78.
80. Caron J, Rochoy M, Gaboriau L, Gautier S. The history of pharmacovigilance. *Therapie*. 2016;71(2):123-8.

81. Marcelo J. Safety of Medicinal Products in the Philippines: Assessment of the Pharmacovigilance System and its Performance. US Agency for International Development by the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program. Arlington, VA: Management Sciences for Health; 2013.
82. Edwards IR, Olsson S. The WHO international drug monitoring programme. Side Effects of Drugs Annual. 2002;25:589-98.
83. Demortain D. The tools of globalization: ways of regulating and the structure of the international regime for pharmaceuticals. Review of International Political Economy. 2015;22(6):1249-75.
84. Uppsala Monitoring Centre. WHO Programme for International Drug Monitoring Uppsala, Sweden: Uppsala Monitoring Centre; 2020 [Available from: [https://www.who-umc.org/global-pharmacovigilance/who-programme-for-international-drug-monitoring./](https://www.who-umc.org/global-pharmacovigilance/who-programme-for-international-drug-monitoring/)]
85. Strengthening Pharmaceutical Systems (SPS) Program. Indicator-Based Pharmacovigilance Assessment Tool: Manual for Conducting Assessments in Developing Countries. U.S.; 2009.
86. Allabi AC, Nwokike J. A situational analysis of pharmacovigilance system in Republic of Benin. Journal of Pharmacovigilance. 2014.
87. Choi HL, Nwokike J, Boni A, Lee Dv. Comprehensive Assessment of Pharmacovigilance Systems and their Performance in Sub-Saharan Africa. Second Global Symposium on Health Systems Research; Beijing, China: The SIAPS Program is funded by the US Agency for International Development under cooperative agreement; 2012.

88. Suwankesawong W, Dhippayom T, Tan-Koi WC, Kongkaew C. Pharmacovigilance activities in ASEAN countries. *Pharmacoepidemiology and Drug Safety*. 2016;25(9):1061-9.
89. Qato DM. Current state of pharmacovigilance in the Arab and Eastern Mediterranean region : results of a 2015 survey. *International Journal of Pharmacy Practice*. 2017.
90. Mazzitello C, Esposito S, De Francesco AE, Capuano A, Russo E, De Sarro G. Pharmacovigilance in Italy: an overview. *Journal of Pharmacology & Pharmacotherapeutics*. 2013;4(Suppl1):S20.
91. Zhao Y, Wang T, Li G, Sun S. Pharmacovigilance in China : development and challenges. *International Journal of Clinical Pharmacy*. 2018;40(4):823-31.
92. Hagemann U, Paeschke N. How Pharmacovigilance is Organized in Germany. In *Mann's Pharmacovigilance* (eds E.B. Andrews and N. Moore). *Mann's Pharmacovigilance 2014*. p. 207-12.
93. Shalviri G, Valadkhani M, Dinarvand R. Ten years pharmacovigilance activities in Iran. *Iran J Public Health*. 2009;38(Suppl 1):162-5.
94. Salehifar E, Ala S, Amini M, Azhdari E, Mir-Shafa F. The role of Clinical Pharmacists in the improvement of a pharmacovigilance system : A review of the reported adverse drug reactions during 2004-2010 in Mazandaran Province of Iran. *Journal of Pharmaceutical Care*. 2013 :8-12.
95. Edwards IR, Biriell C. Harmonisation in Pharmacovigilance. *Drug Safety*. 1994;10(2):93-102.

96. WHO Collaborating Centre for Drug Statistics Methodology. The Anatomical Therapeutic Chemical (ATC) classification system and the Defined Daily Dose (DDD) Oslo, Norway: WHO Collaborating Centre; 2020 [Available from : [https://www.whocc.no./](https://www.whocc.no/)
97. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). *Drug Safety*. 1999;20(2):109-17.
98. Bushardt RL, Massey EB, Simpson TW, Ariail JC, Simpson KN. Polypharmacy: misleading, but manageable. *Clin Interv Aging*. 2008;3(2):383.
99. Angamo MT, Curtain CM, Chalmers L, Yilma D, Bereznicki L. Predictors of adverse drug reaction-related hospitalisation in Southwest Ethiopia : A prospective cross-sectional study. *PLOS One*. 2017;12(10):e0186631.
100. Baniasadi S, Habibi M, Haghgoo R, Karimi Gamishan M, Dabaghzadeh F, Farasatinasab M, et al. Increasing the number of adverse drug reactions reporting: the role of clinical pharmacy residents. *Iranian Journal of Pharmaceutical Research : IJPR*. 2014;13(1):291-7.
101. Miguel A, Azevedo LF, Araújo M, Pereira AC. Frequency of adverse drug reactions in hospitalized patients : a systematic review and meta-analysis. *Pharmacoepidemiology and Drug Safety*. 2012;21(11):1139-54.
102. Cano FG, Rozenfeld S. Adverse drug events in hospitals : a systematic review. *Cadernos de Saúde Pública*. 2009;25 :S360-S72.
103. Mugosa S, Bukumirić Z, Kovacević A, Bosković A, Protić D, Todorović Z. Adverse drug reactions in hospitalized cardiac patients : characteristics and risk factors. *Vojnosanitetski pregled*. 2015;72(11):975-81.

104. Dahiya S. A systematic review of risk factors of adverse drug reactions in hospitalized patients. *Asian Journal of Pharmaceutical and Clinical Research*. 2018;11(10):25-9.
105. Hug BL, Keohane C, Seger DL, Yoon C, Bates DW. The costs of adverse drug events in community hospitals. *Jt Comm J Qual Patient Saf*. 2012;38(3):120-6.
106. Hoogervorst-Schilp J, Langelaan M, Spreeuwenberg P, de Bruijne MC, Wagner C. Excess length of stay and economic consequences of adverse events in Dutch hospital patients. *BMC Health Services Research*. 2015;15(1):531.
107. Khan LM. Comparative epidemiology of hospital-acquired adverse drug reactions in adults and children and their impact on cost and hospital stay-a systematic review. *European Journal of Clinical Pharmacology*. 2013;69(12):1985-96.
108. Rottenkolber D, Schmiedl S, Rottenkolber M, Farker K, Salje K, Mueller S, et al. Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations. *Pharmacoepidemiology and Drug Safety*. 2011;20(6):626-34.
109. Fasipe OJ, Akhideno PE, Owhin OS. The observed effect of adverse drug reactions on the length of hospital stay among medical inpatients in a Nigerian University Teaching Hospital. *Toxicology Research and Application*. 2019;3:2397847319850451.
110. Elzagallaai A, Greff M, Rieder M. Adverse Drug Reactions in Children: The Double-Edged Sword of Therapeutics. *Clinical Pharmacology & Therapeutics*. 2017;101(6):725-35.
111. Kurian J, Mathew J, Sowjanya K, Chaitanya KRK, Ramesh M, Sebastian J, et al. Adverse Drug Reactions in Hospitalized Pediatric Patients: A Prospective Observational Study. *The Indian Journal of Pediatrics*. 2016;83(5):414-9.

112. Nogueira Guerra L, Herdeiro MT, Ribeiro-Vaz I, Clérigo MIP, Rocha C, Araújo A, et al. Adverse drug reactions in children: a ten-year review of reporting to the Portuguese Pharmacovigilance System. *Expert Opinion on Drug Safety*. 2015;14(12):1805-13.
113. Oscanoa T, Lizaraso F, Carvajal A. Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis. *European Journal of Clinical Pharmacology*. 2017;73(6):759-70.
114. Carnovale C, Gentili M, Fortino I, Merlino L, Clementi E, Radice S, et al. The importance of monitoring adverse drug reactions in elderly patients: the results of a long-term pharmacovigilance programme. *Expert Opinion on Drug Safety*. 2016;15(2):131-9.
115. Schurig AM, Böhme M, Just KS, Scholl C, Dormann H, Plank-Kiegele B, et al. Adverse Drug Reactions (ADR) and Emergencies. *Dtsch Arztebl Int*. 2018;115(15):251-8.
116. Rydberg DM, Holm L, Engqvist I, Fryckstedt J, Lindh JD, Stiller C-O, et al. Adverse Drug Reactions in a Tertiary Care Emergency Medicine Ward - Prevalence, Preventability and Reporting. *PLOS One*. 2016;11(9):e0162948.
117. Sugioka M, Tachi T, Mizui T, Koyama A, Murayama A, Katsuno H, et al. Effects of the number of drugs used on the prevalence of adverse drug reactions in children. *Scientific Reports*. 2020;10(1):21341.
118. U.S. Food and Drug Administration. Preventable Adverse Drug Reactions: A Focus on Drug Interactions U.S.: FDA; 2018 [Available from: <https://www.fda.gov/drugs/drug-interactions-labeling/preventable-adverse-drug-reactions-focus-drug-interactions>].

119. Patidar D, Rajput MS, Nirmal NP, Savitri W. Implementation and evaluation of adverse drug reaction monitoring system in a tertiary care teaching hospital in Mumbai, India. *Interdiscip Toxicol.* 2013;6(1):41-6.
120. Conforti A, Opri S, D'Incau P, Sottosanti L, Moretti U, Ferrazin F, et al. Adverse drug reaction reporting by nurses: analysis of Italian pharmacovigilance database. *Pharmacoepidemiology and Drug Safety.* 2012;21(6):597-602.
121. Rosli R, Dali AF, Aziz NA, Ming LC, Manan MM. Reported Adverse Drug Reactions in Infants : A Nationwide Analysis in Malaysia. *Frontiers in pharmacology.* 2017;8:30.
122. Criado PR, Criado RF, Maruta CW, Machado Filho C. Histamine, histamine receptors and antihistamines : new concepts. *Anais brasileiros de dermatologia.* 2010;85(2):195-210.
123. de Vries TW, van Hunsel F. Adverse drug reactions of systemic antihistamines in children in the Netherlands. *Archives of Disease in Childhood.* 2016;101(10):968.
124. Niedrig D, Maechler S, Hoppe L, Corti N, Kovari H, Russmann S. Drug safety of macrolide and quinolone antibiotics in a tertiary care hospital : administration of interacting co-medication and QT prolongation. *European Journal of Clinical Pharmacology.* 2016;72(7):859-67.
125. Doña I, Moreno E, Pérez-Sánchez N, Andreu I, Hernández Fernandez de Rojas D, Torres MJ. Update on Quinolone Allergy. *Current Allergy and Asthma Reports.* 2017;17(8):56.
126. Shalviri G, Yousefian S, Gholami K. Adverse events induced by ceftriaxone : a 10-year review of reported cases to Iranian Pharmacovigilance Centre. *Journal of Clinical Pharmacy and Therapeutics.* 2012;37(4):448-51.

127. Izadpanah F, Amini M, Asadollahpour A, Esfahani Z, Yousofi M. Adverse Drug Reactions in Mazandaran Province, Iran, 2004–2018. *Journal of Mazandaran University of Medical Sciences*. 2020;30(185):96–103.
128. Jung IY, Kim JJ, Lee SJ, Kim J, Seong H, Jeong W, et al. Antibiotic-related adverse drug reactions at a tertiary care hospital in South Korea. *BioMed Research International*. 2017;2017:4304973.
129. Giardina C, Cutroneo PM, Mocciaro E, Russo GT, Mandraffino G, Basile G, et al. Adverse Drug Reactions in Hospitalized Patients: Results of the FORWARD (Facilitation of Reporting in Hospital Ward) Study. *Frontiers in pharmacology*. 2018;9.(۳۵۰)
130. Chan SL, Ang X, Sani LL, Ng HY, Winther MD, Liu JJ, et al. Prevalence and characteristics of adverse drug reactions at admission to hospital: a prospective observational study. *British Journal of Clinical Pharmacology*. 2016;82(6):1636–46.
131. Mandavi, D'Cruz S, Sachdev A, Tiwari P. Adverse drug reactions & their risk factors among Indian ambulatory elderly patients. *Indian J Med Res*. 2012;136(3):404–10.
132. Ognibene S, Vazzana N, Giumelli C, Savoldi L, Braglia L, Chesi G. Hospitalisation and morbidity due to adverse drug reactions in elderly patients: a single-centre study. *Internal Medicine Journal*. 2018;48(10):1192–7.
133. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. *PLOS One*. 2009;4(2):e4439-e.



134. Safari M, Zandian Z, Vakili S, Rasuli B. Adverse drug reactions causing admission to a Pediatric Hospital in Hamedan-Iran: a 2 years study. *Iranian Journal of Pharmacology and Therapeutics*. 2015;13(1):26-0.
135. Hatam N, Askarian M, Moravveji AR, Assadian O. Economic burden of inappropriate antibiotic use for prophylactic purpose in shiraz, iran. *Iran Red Crescent Med J*. 2011;13(4):234-8.
136. Askarian M, Maharlouie N. Irrational Antibiotic Use among Secondary School Teachers and University Faculty Members in Shiraz, Iran. *Int J Prev Med*. 2012;3(12):839-45.
137. Gholami K, Babaie F, Shalviri G, Javadi MR, Faghihi T. Pediatric Hospital Admission Due to Adverse Drug Reactions : Report from a Tertiary Center . *J Res Pharm Pract*. 2015;4(4):212-5.
138. Baniasadi S, Fahimi F. Adverse Drug Reactions in a Pulmonary Teaching Hospital: Incidence, Pattern, Seriousness, and Preventability. *Current Drug Safety*. 2011;6(4):230-6.
139. Iran SCo. Findings of national population and household census Iran : Statistical Centre of Iran; 2020 [Available from: <https://www.amar.org.ir/english/Population-and-Housing-Censuses>].
140. Ministry of Health and Medical Education. Hospital information and statistics website in Iran Iran: Ministry of Health and Medical Education; 2020 [Available from: <http://avab.behdasht.gov.ir/rbp>].
141. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. *Statistics in Medicine*. 2000;19(3):335-51.

142. Kourorian Z, Fattahi F, Pourpak Z, Rasoolinejad M, Gholami K. Adverse drug reactions in an Iranian department of adult infectious diseases. *Eastern Mediterranean Health Journal*. 2009;15(6):1351-7.
143. Moore TJ, Furberg CD, Mattison DR, Cohen MR. Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014. *Pharmacoepidemiology and Drug Safety*. 2016;25(6):713-8.
144. Srba J, Descikova V, Vlcek J. Adverse drug reactions : Analysis of spontaneous reporting system in Europe in 2007-2009. *European Journal of Clinical Pharmacology*. 2012;68(7):1057-63.
145. Guo X-j, Ye X-f, Wang X-x, Wang J, Shi W-t, Gao Q-b, et al. Reporting patterns of adverse drug reactions over recent years in China : analysis from publications. *Expert Opinion on Drug Safety*. 2015;14(2):191-8.
146. Motola D, Melis M, Lo Bianco S, Buccellato E, Biagi C, Vaccheri A. Ten years of pharmacovigilance in Italy : the experience of Emilia-Romagna region in the monitoring of drug's safety profile. *Expert Opinion on Drug Safety*. 2014;13(7):867-73.
147. Kopečná E, Deščíková V, Vlček J, Mladá J. Adverse drug reaction reporting in the Czech Republic 2005-2009. *International Journal of Clinical Pharmacy*. 2011;33(4):683-9.
148. Wong SX, Tham MY, Goh CL, Cheong HH, Chan SY. Spontaneous cutaneous adverse drug reaction reports—An analysis of a 10-year dataset in Singapore. *Pharmacology Research & Perspectives*. 2019;7(2):e00469.

149. Ozcan G, Aykac E, Kasap Y, Nemutlu NT, Sen E, Aydinkarahaliloglu ND. Adverse Drug Reaction Reporting Pattern in Turkey : Analysis of the National Database in the Context of the First Pharmacovigilance Legislation. *Drugs Real World Outcomes*. 2016;3(1):33-43.
150. Aagaard L, Strandell J, Melskens L, Petersen PS, Hansen EH. Global patterns of adverse drug reactions over a decade. *Drug Safety*. 2012;35(12):1171-82.
151. Morimoto T, Sakuma M, Matsui K, Kuramoto N, Toshiro J, Murakami J, et al. Incidence of adverse drug events and medication errors in Japan : the JADE study. *Journal of General Internal Medicine*. 2011;26(2):148-53.
152. Zimlichman E, Gueta I, Daliyot D, Ziv A, Oberman B, Hochman O, et al. Adverse Drug Event Rate in Israeli Hospitals : Validation of an International Trigger Tool and an International Comparison Study. *Isr Med Assoc J*. 2018;20(11):665-9.
153. Scripcaru G, Mateus C, Nunes C. A decade of adverse drug events in Portuguese hospitals : space-time clustering and spatial variation in temporal trends. *BMC Pharmacology and Toxicology*. 2017;18(1):34.
154. Wu T-Y, Jen M-H, Bottle A, Molokhia M, Aylin P, Bell D, et al. Ten-year trends in hospital admissions for adverse drug reactions in England 1999-2009. *Journal of the Royal Society of Medicine*. 2010;103(6):239-50.
155. Martins AC, Giordani F, Guaraldo L, Tognoni G, Rozenfeld S. Adverse drug events identified in hospitalized patients in Brazil by International Classification of Diseases (ICD-10) code listings. *Cadernos de Saúde Pública*. 2018;34:e00222417.

156. Rosli R, Ming LC, Abd Aziz N, Manan MM. A Retrospective Analysis of Spontaneous Adverse Drug Reactions Reports Relating to Paediatric Patients. *PLOS One*. 2016;11(6):e0155385.
157. Bourgeois FT, Shannon MW, Valim C, Mandl KD. Adverse drug events in the outpatient setting: an 11 year national analysis. *Pharmacoepidemiology and Drug Safety*. 2010;19(9):901-10.
158. Zhang H, Du W, Gnjidic D, Chong S, Lancsar E, Glasgow N. Trends in adverse drug reactions related hospitalisations over 13 years in New South Wales, Australia. *Internal Medicine Journal*. 2018.
159. Ermias A, Gurmesa G, Mesfin M, Mengistu A. Adverse drug reaction monitoring in Ethiopia: Analysis of case reports, 2002-2007. *Ethiopian Journal of Health Development*. 2011;25(2):168-73.
160. Leone S. 5-Year Trend of Reporting Adverse Drug Reaction: an Italian General Practice Experience. *EC Pharmacology and Toxicology*. 2017;5:29-37.
161. McMahon CG, Cahir CA, Kenny RA, Bennett K. Inappropriate prescribing in older fallers presenting to an Irish emergency department. *Age and Ageing*. 2014;43(1):44-50.
162. Shin YS, Lee YW, Choi YH, Park B, Jee YK, Choi SK, et al. Spontaneous reporting of adverse drug events by Korean regional pharmacovigilance centers. *Pharmacoepidemiology and Drug Safety*. 2009;18(10):910-5.
163. Alomar MJ. Factors affecting the development of adverse drug reactions (Review article). *Saudi Pharmaceutical Journal*. 2014;22(2):83-94.

164. Scripcaru G, Mateus C, Nunes C. A decade of adverse drug events in Portuguese hospitals : space-time clustering and spatial variation in temporal trends. *BMC Pharmacol Toxicol.* 2017;18(1):34.
165. Alatawi YM, Hansen RA. Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). *Expert Opinion on Drug Safety.* 2017;16(7):761-7.
166. Bäckström M, Mjörndal T, Dahlgvist R. Under-reporting of serious adverse drug reactions in Sweden. *Pharmacoepidemiology and Drug Safety.* 2004;13(7):483-7.
167. Moride Y, Haramburu F, Requejo AA, Begaud B. Under-reporting of adverse drug reactions in general practice. *British Journal of Clinical Pharmacology.* 1997;43(2):177-81.
168. Alvarez-Requejo A, Carvajal A, Bégaud B, Moride Y, Vega T, Arias LHM. Under-reporting of adverse drug reactions Estimate based on a spontaneous reporting scheme and a sentinel system. *European Journal of Clinical Pharmacology.* 1998;54(6):483-8.
169. Hohl CM, Kuramoto L, Yu E, Rogula B, Stausberg J, Sobolev B. Evaluating adverse drug event reporting in administrative data from emergency departments : a validation study. *BMC Health Services Research.* 2013;13(1):473.
170. Lugardon S, Desboeuf K, Fernet P, Montastruc JL, Lapeyre-Mestre M. Using a capture-recapture method to assess the frequency of adverse drug reactions in a French university hospital. *British Journal of Clinical Pharmacology.* 2006;62(2):225-31.
171. Kasliwal R. Spontaneous reporting in pharmacovigilance : strengths, weaknesses and recent methods of analysis. *Journal of Clinical and Preventive Cardiology.* 2012;1 :20-3.

172. Cheema E, Haseeb A, Khan TM, Sutcliffe P, Singer DR. Barriers to reporting of adverse drugs reactions: a cross sectional study among community pharmacists in United Kingdom. *Pharmacy Practice (Granada)*. 2017;15.(3)
173. Elkalmi RM, Hassali MA, Ibrahim MIM, Jamshed SQ, Al-lela OQB. Community Pharmacists' Attitudes, Perceptions, and Barriers Toward Adverse Drug Reaction Reporting in Malaysia : A Quantitative Insight. *Journal of Patient Safety*. 2014;10(2).
174. Hughes ML, Weiss M. Adverse drug reaction reporting by community pharmacists—The barriers and facilitators. *Pharmacoepidemiology and Drug Safety*. 2019;28(12):1552-9.
175. Olowofela A. Evaluation of pharmacovigilance system performance in South-South Nigeria. France : Université de Bordeaux; 2018.
176. Harmonization DR. Good Pharmacovigilance Practices for the Americas. 2011.
177. Neubert A, Dormann H, Prokosch H-U, Bürkle T, Rascher W, Sojer R, et al. E-pharmacovigilance : development and implementation of a computable knowledge base to identify adverse drug reactions. *British Journal of Clinical Pharmacology*. 2013;76(S1):69-77.
178. Sainul Abideen P. Practical implications of spontaneous adverse drug reaction reporting system in hospitals-an overview. *Asian Journal of Pharmaceutical and Clinical Research*. 2013;6(4).
179. Paudyal V, Al-Hamid A, Bowen M, Hadi MA, Hasan SS, Jalal Z, et al. Interventions to improve spontaneous adverse drug reaction reporting by healthcare professionals and patients : systematic review and meta-analysis. *Expert Opinion on Drug Safety*. 2020;19(9):1173-91.

180. Khalili M, Mesgarpour B, Sharifi H, Daneshvar Dehnavi S, Haghdoost AA. Interventions to improve adverse drug reaction reporting: A scoping review. *Pharmacoepidemiology and Drug Safety*. 2020;29(9):965-92.
181. Phansalkar S, Hoffman JM, Nebeker JR, Hurdle JF. Pharmacists versus nonpharmacists in adverse drug event detection: A meta-analysis and systematic review. *American Journal of Health-System Pharmacy*. 2007;64(8):842-9.
182. Tandon VR, Mahajan V, Khajuria V, Gillani Z. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India. *Indian J Pharmacol*. 2015;47(1):65-71.
183. Nadew SS, Beyene KGM, Beza SW. Adverse drug reaction reporting practice and associated factors among medical doctors in government hospitals in Addis Ababa, Ethiopia. *PLOS One*. 2020;15(1):e0227712.
184. Alshakka M, Im I, Palaian S. Importance of consumer pharmacovigilance system in developing countries: a case of malaysia. *Journal of Clinical and Diagnostic Research*. 2010.
185. Ribeiro-Vaz I, Santos CC, Cruz-Correia R. Promoting adverse drug reaction reporting: comparison of different approaches. *Revista de Saúde Pública*. 2016;50:14.
186. Troya MI, Greene MC, Santos CG, Shultz JM. Conducting a desk review to inform the mental health and psychosocial support response to the 2016 Ecuador earthquake. *Disaster Health*. 2016;3(4):90-101.
187. Hashjin AA, Delgoshaei B, Kringos DS, Tabibi SJ, Manouchehri J, Klazinga NS. Implementing hospital quality assurance policies in Iran: Balancing licensing, annual evaluation,

inspections and quality management systems. *International Journal of Health Care Quality Assurance*. 2015;28(4):343-55a.

188. Marcelo J. *Safety of Medicinal Products in the Philippines: Assessment of the Pharmacovigilance System and its Performance* Arlington, VA: Management Sciences for Health: Submitted to the US Agency for International Development by the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program; 2013 [cited 2020 31 March ]. Available from: <https://apps.who.int/medicinedocs/en/m/abstract/Js22350en/>

189. Cerruti L, Lebel D, Van Hees T, Bourdon O, Bonnabry P, Spinewine A, et al. Pilot Study about Hospital Pharmacy Residents' Perception of Pharmacovigilance in Belgium, France, Canada and Switzerland. *Canadian Journal of Clinical Pharmacology*. 2015;22(2):e179.

190. Hartman J, Härmark L, van Puijenbroek E. A global view of undergraduate education in pharmacovigilance. *European Journal of Clinical Pharmacology*. 2017;73(7):891-9.

191. Ampadu HH, Hoekman J, Arhinful D, Amoama-Dapaah M, Leufkens HGM, Dodoo ANO. Organizational capacities of national pharmacovigilance centres in Africa: assessment of resource elements associated with successful and unsuccessful pharmacovigilance experiences. *Global Health*. 2018;14(1):109.

192. Abiri OT, Johnson WCN. Pharmacovigilance systems in resource-limited settings: an evaluative case study of Sierra Leone. *Journal of Pharmaceutical Policy and Practice*. 2019;12(1):13.

193. Van Eekeren R, Rolfes L, Koster A, Magro L, Gurusurthy P, Ramimmy H, et al. What Future Healthcare Professionals Need to Know About Pharmacovigilance: Introduction of the WHO



- PV Core Curriculum for University Teaching with Focus on Clinical Aspects. *Drug Safety*. 2018;41:1-9.
194. Goel D, Farooq M. Impact of educational intervention on knowledge, attitude and practice of pharmacovigilance among interns. *Advances in Human Biology*. 2017;7(2):75-9.
195. Shepherd G, Mohorn P, Yacoub K, May DW. Adverse drug reaction deaths reported in United States vital statistics, 1999-2006. *Annals of Pharmacotherapy*. 2012;46(2):169-75.
196. Oosterhuis I, van Hunsel FP, van Puijenbroek EP. Expectations for feedback in adverse drug reporting by healthcare professionals in the Netherlands. *Drug Safety*. 2012;35(3):221-32.
197. Vial T. French pharmacovigilance: Missions, organization and perspectives. *Therapie*. 2016;71(2):143-50.
198. Maigetter K, Pollock AM, Kadam A, Ward K, Weiss MG. Pharmacovigilance in India, Uganda and South Africa with reference to WHO's minimum requirements. *Int J Health Policy Manag*. 2015;4(5):295-305.
199. Santoro A, Genov G, Spooner A, Raine J, Arlett P. Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works. *Drug Safety*. 2017;40(10):855-69.
200. Alshammari TM, Alshakka M, Aljadhey H. Pharmacovigilance system in Saudi Arabia. *Saudi Pharmaceutical Journal*. 2017;25(3):299-305.
201. Chan CL, San Ang P, Li SC. A survey on pharmacovigilance activities in Asean and selected non-Asean countries, and the use of quantitative signal detection algorithms. *Drug Safety*. 2017;40(6):517-30.

202. Farcaş A, Măhălean A, Bulik NB, Leucuta D, Mogoşan C. New safety signals assessed by the Pharmacovigilance Risk Assessment Committee at EU level in 2014-2017. *Expert Review of Clinical Pharmacology*. 2018;11(10):1045-51.
203. Suwankesawong W, Dhipayom T, Tan-Koi W-C, Kongkaew C. Pharmacovigilance activities in ASEAN countries. *Pharmacoepidemiology and Drug Safety*. 2016;25(9):1061-9.
204. Geer M, Koul P, Tanki S, Shah M. Frequency, types, severity, preventability and costs of adverse drug reactions at a tertiary care hospital. *Journal of Pharmacological and Toxicological Methods*. 2016;81 :323-34.
205. Pattanaik S, Dhamija P, Malhotra S, Sharma N, Pandhi P. Evaluation of cost of treatment of drug-related events in a tertiary care public sector hospital in Northern India : a prospective study. *British Journal of Clinical Pharmacology*. 2009;67(3):363-9.
206. Patel K, Kedia M, Bajpai D, Mehta S, Kshirsagar N, Gogtay N. Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre : a prospective study. *BMC Clin Pharmacol*. 2007;7(1):8.
207. Kane-Gill SL, Jacobi J, Rothschild JM. Adverse drug events in intensive care units : Risk factors, impact, and the role of team care. *Critical Care Medicine*. 2010;38.
208. Wilbur K. Pharmacovigilance in the middle east. *Drug Safety*. 2013;36(1):25-30.
209. Bate A, Beckmann J, Dodoo A, Härmark L, Hartigan-Go K, Hegerius A, et al. Developing a crowdsourcing approach and tool for pharmacovigilance education material delivery. *Drug Safety*. 2017;40(3):191-9.

210. Hans M, Gupta SK. Comparative evaluation of pharmacovigilance regulation of the United States, United Kingdom, Canada, India and the need for global harmonized practices. *Perspectives in Clinical Research*. 2018;9(4):170.
211. Haynes K. Electronic Health Record, Transactional Insurance Claims, and Distributed Databases in Pharmacovigilance. *Evidence-Based Pharmacovigilance* : Springer; 2018. p. 135-48.
212. Ritchie J, Spencer L. Qualitative data analysis for applied policy research. *The Qualitative Researcher's Companion*. 2002;573(2002):305-29.
213. Jalali R. Qualitative research sampling. *Journal of Qualitative Research in Health Sciences*. 2013;1(4):310-20.
214. Hennink MM, Kaiser BN, Marconi VC. Code Saturation Versus Meaning Saturation : How Many Interviews Are Enough? *Qualitative Health Research*. 2016;27(4):591-608.
215. Nowell LS, Norris JM, White DE, Moules NJ. Thematic Analysis: Striving to Meet the Trustworthiness Criteria. *International Journal of Qualitative Methods*. 2017;16(1):1609406917733847.
216. Guba EG, Lincoln YS. Epistemological and methodological bases of naturalistic inquiry. *ECTJ*. 1982;30(4):233-52.
217. Maryam E-I, Sarah M, Amin R, Mehrdad A, Leila K, Kaveh E. Adverse Drug Reactions : Knowledge, Attitude and Practice of Pharmacy. *Journal of Pharmaceutical Care*. 2015;1.(۴)
218. Nichols V, Thé riault-Dubé I, Touzin J, Delisle JF, Lebel D, Bussiè res JF, et al. Risk perception and reasons for noncompliance in pharmacovigilance : a qualitative study conducted in Canada. *Drug Safety*. 2009;32(7):579-90.

219. John LJ, Arifulla M, Cheriathu JJ, Sreedharan J. Reporting of adverse drug reactions : an exploratory study among nurses in a teaching hospital, Ajman, United Arab Emirates. *DARU Journal of Pharmaceutical Sciences*. 2012;20(1):44.
220. Moinuddin K, Ali S, Al-Aqqad AQ, Salem SO, Al-Dossari MA, Ananzeh AM, et al. Knowledge and Attitude of Health-Care Professionals Toward Adverse Drug Reactions Reporting at King Saud Medical City. *J Pharm Bioallied Sci*. 2018;10(1):29-34.
221. Yu YM, Kim S, Choi KH, Jeong KH, Lee E. Impact of knowledge, attitude and preceptor behaviour in pharmacovigilance education. *Basic & Clinical Pharmacology & Toxicology*. 2019;124(5):591-9.
222. Vallano A, Cereza G, Pedròs C, Agustí A, Danés I, Aguilera C, et al. Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital. *British journal of clinical pharmacology*. 2005;60(6):653-8.
223. Khalili H, Mohebbi N, Hendoiee N, Keshtkar A-A, Dashti-Khavidaki S. Improvement of knowledge, attitude and perception of healthcare workers about ADR, a pre- and post-clinical pharmacists' interventional study. *BMJ Open*. 2012;2(1):e000367.
224. Ganesan S, Sandhiya S, Reddy KC, Subrahmanyam DK, Adithan C. The Impact of the Educational Intervention on Knowledge, Attitude, and Practice of Pharmacovigilance toward Adverse Drug Reactions Reporting among Health-care Professionals in a Tertiary Care Hospital in South India. *J Nat Sci Biol Med*. 2017;8(2):203-9.

225. Güner MD, Ekmekci PE. Healthcare professionals' pharmacovigilance knowledge and adverse drug reaction reporting behavior and factors determining the reporting rates. *Journal of Drug Assessment*. 2019;8(1):13-20.
226. Hussain R, Hassali MA, Rana SM. Evaluation of an educational intervention on physicians' knowledge about adverse drug reaction reporting system. *Journal of Public Health*. 2019:1-4.
227. Vo T, Dang T, Nguyen T, Nguyen D. An Educational Intervention to Improve Adverse Drug Reaction Reporting: An Observational Study in a Tertiary Hospital in Vietnam. *Archives of Pharmacy Practice*. 2020;1:32.
228. Elkalmi RM, Hassali MA, Ibrahim MIM, Liau SY, Awaisu A. A qualitative study exploring barriers and facilitators for reporting of adverse drug reactions (ADRs) among community pharmacists in Malaysia. *Journal of Pharmaceutical Health Services Research*. 2011;2(2):71-8.
229. Ribeiro-Vaz I, Silva A-M, Costa Santos C, Cruz-Correia R. How to promote adverse drug reaction reports using information systems - a systematic review and meta-analysis. *BMC Med Inform Decis Mak*. 2016;16:27.-
230. Prang IW, Jelsness-Jørgensen L-P. Should I report? A qualitative study of barriers to incident reporting among nurses working in nursing homes. *Geriatric Nursing*. 2014;35(6):441-7.
231. Katusiime B, Semakula D, Lubinga SJ. Adverse drug reaction reporting among health care workers at Mulago National Referral and Teaching hospital in Uganda. *African Health Sciences*. 2015;15(4):1308-17.

232. Hadi MA, Helwani R, Long CM. Facilitators and barriers towards adverse drug reaction reporting: perspective of Malaysian hospital pharmacists. *Journal of Pharmaceutical Health Services Research*. 2013;4(3):155-8.
233. Williams SD, Phipps DL, Ashcroft DM. Understanding the attitudes of hospital pharmacists to reporting medication incidents: a qualitative study. *Research in Social and Administrative Pharmacy*. 2013;9(1):80-9.
234. Haider N, Mazhar F. Factors associated with underreporting of adverse drug reactions by nurses: A narrative literature review. *Saudi Journal for Health Sciences*. 2017;6(2):71-6.
235. Ali S, Egunsola O, Al-Dossari DS, Al-Zaagi IA. Adverse drug reaction reporting in a large tertiary hospital in Saudi Arabia: results of an incentive strategy. *Ther Adv Drug Saf*. 2018;9(10):585-90.
236. Li R, Zaidi STR, Chen T, Castelino R. Effectiveness of interventions to improve adverse drug reaction reporting by healthcare professionals over the last decade: A systematic review. *Pharmacoepidemiology and Drug Safety*. 2020;29(1):1-8.
237. Molokhia M, Tanna S, Bell D. Improving reporting of adverse drug reactions: systematic review. *Clinical Epidemiology*. 2009;1:75.
238. Haji Aghajani M, Haghdoost A, Noori Hekmat S, Janbabaee G, Maher A, Javadi A, et al. Geographical distribution of different groups of medical staff in Iran in 2016 and the estimates for 2026. *Iranian Journal of Epidemiology*. 2018;13:71-84.

239. Noori Hekmat S, Hashemi H, Haghdoost A, Haji Aghajani M, Janbabae G, Maher A, et al. Specialized and geographic distribution of specialists in Iran in 2016 and its estimates in 2026. *Iranian Journal of Epidemiology*. 2018;13 :122-32.
240. Hussain R, Hassali MA, Muneswarao J, Hashmi F. Physicians' understanding and practices of Pharmacovigilance : qualitative experience from A lower middle-income country. *International Journal of Environmental Research and Public Health*. 2020;17(7):2209 .
241. Visacri MB, Souza CMd, Pimentel R, Barbosa CR, Sato CMS, Granja S, et al. Pharmacovigilance in oncology : pattern of spontaneous notifications, incidence of adverse drug reactions and under-reporting. *Brazilian Journal of Pharmaceutical Sciences*. 2014;50 :411-22.
242. Clavenna A, Bonati M. Adverse drug reactions in childhood : a review of prospective studies and safety alerts. *Archives of Disease in Childhood*. 2009;94(9):724.
243. Grossoehme DH. Overview of qualitative research. *Journal of Health Care Chaplaincy*. 2014;20(3):109-22.
244. Valerio MA, Rodriguez N, Winkler P, Lopez J, Dennison M, Liang Y, et al. Comparing two sampling methods to engage hard-to-reach communities in research priority setting. *BMC Medical Research Methodology*. 2016;16(1):146.
245. McEwen J, Vestergaard LS, Sanburg AL. Pacific Island Pharmacovigilance : The Need for a Different Approach. *Drug Safety*. 2016;39(10):891-4.

246. Nguyen K-D, Nguyen P-T, Nguyen H-A, Roussin A, Montastruc J-L, Bagheri H, et al. Overview of pharmacovigilance system in Vietnam: lessons learned in a resource-restricted Country. *Drug Safety*. 2018;41(2):151-9.
247. Alshammari TM, Mendi N, Alenzi KA, Alsowaida Y. Pharmacovigilance Systems in Arab Countries: Overview of 22 Arab Countries. *Drug Safety*. 2019;42(7):849-68.
248. Mazzitello C, Esposito S, De Francesco AE, Capuano A, Russo E, De Sarro G. Pharmacovigilance in Italy: An overview. *J Pharmacol Pharmacother*. 2013;4(Suppl 1):S20-S8.
249. Alomar M, Palaian S, Al-Tabakha MM. Pharmacovigilance in perspective: drug withdrawals, data mining and policy implications. *F1000Research*. 2019;8:2109.
250. Mehta U, Dheda M, Steel G, Blockman M, Ntilivamunda A, Maartens G, et al. Strengthening pharmacovigilance in South Africa. *SAMJ: South African Medical Journal*. 2014;104:104-6.
251. Setayesh S, Mackey TK. Addressing the impact of economic sanctions on Iranian drug shortages in the joint comprehensive plan of action: promoting access to medicines and health diplomacy. *Globalization and Health*. 2016;12(1):31.
252. Kokabisaghi F. Assessment of the Effects of Economic Sanctions on Iranians' Right to Health by Using Human Rights Impact Assessment Tool: A Systematic Review. *International Journal of Health Policy and Management*. 2018;7(5):374-93.



253. Bakare N, Edwards IR, Stergachis A, Pal S, Holmes CB, Lindquist M, et al. Global pharmacovigilance for antiretroviral drugs: overcoming contrasting priorities. *PLoS Med.* 2011;8(7):e1001054-e.
254. Lihite RJ, Lahkar M. An update on the pharmacovigilance programme of India. *Frontiers in pharmacology.* 2015;6:194.
255. World Health Organization. The safety of medicines in public health programmes: pharmacovigilance, an essential tool. Geneva: WHO; 2006. Report No.: 9241593911.
256. Kalaiselvan V, Thota P, Singh GN. Pharmacovigilance Programme of India: Recent developments and future perspectives. *Indian J Pharmacol.* 2016;48(6):624-8.
257. Kalikar M, Dakhale G, Shirao M. Effect of educational intervention on awareness of pharmacovigilance among medical undergraduates in a tertiary care teaching hospital. *Perspectives in Clinical Research.* 2020;11(2):92-6.
258. Dheda M. Perspectives on the Emergence of Pharmacovigilance in Public Health Programmes in South Africa. *Pharmaceutical Medicine.* 2016;30(4):213-9.
259. Cortes-Serra N, Saravia R, Grágeda RM, Apaza A, González JA, Ríos B, et al. Strengthening the Bolivian pharmacovigilance system: New surveillance strategies to improve care for Chagas disease and tuberculosis. *PLOS Neglected Tropical Diseases.* 2020;14(9):e0008370.
260. Kalaiselvan V, Srivastava S, Singh A, Gupta SK. Pharmacovigilance in India: Present Scenario and Future Challenges. *Drug Safety.* 2019;42(3):339-46.

261. Van Puijenbroek EP, Diemont WL, van Grootheest K. Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions. *Drug Safety*. 2003;26(5):293-301.
261. Oliveira JL, Lopes P, Nunes T, Campos D, Boyer S, Ahlberg E, et al. The EU-ADR Web Platform: delivering advanced pharmacovigilance tools. *Pharmacoepidemiology and Drug Safety*. 2013;22(5):459-67.
263. Schutte T, Tichelaar J, Reumerman MO, van Eekeren R, Rolfes L, van Puijenbroek EP, et al. Feasibility and Educational Value of a Student-Run Pharmacovigilance Programme: A Prospective Cohort Study. *Drug Safety*. 2017;40(5):409-18.
264. Nwaiwu O, Oyelade O, Eze C. Evaluation of Pharmacovigilance Practice in Pharmaceutical Companies in Nigeria. *Pharmaceutical Medicine*. 2016;30(5):291-5.
265. Fleuranceau-Morel P. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers. *Pharmacoepidemiology and Drug Safety*. 2002;11(1):37-44.
266. Sharma R, Galib R, Prajapati PK. Good Pharmacovigilance Practice: Accountability of Ayurvedic Pharmaceutical Companies. *Anc Sci Life*. 2017;36(3):167-9.
267. Terblanche A, Meyer JC, Godman B, Summers RS. Impact of a pharmacist-driven pharmacovigilance system in a secondary hospital in the Gauteng Province of South Africa. *Hospital Practice*. 2018;46(4):221-8.

268. Mohammad A, Bheemavarapu H, Khan MU, Khan A, Ahmad A, Hassali MAA, et al. A cross-sectional survey to assess the knowledge, attitudes and common barriers to the reporting of adverse drug reactions by the general public in Malaysia. *Journal of Pharmacy Practice and Research*. 2018;48(4):348-55.
269. Matos C, Härmak L, van Hunsel F. Patient Reporting of Adverse Drug Reactions: An International Survey of National Competent Authorities' Views and Needs. *Drug Safety*. 2016;39(11):1105-16.
270. Al Dweik R, Yaya S, Stacey D, Kohen D. Patients' experiences on adverse drug reactions reporting: a qualitative study. *European Journal of Clinical Pharmacology*. 2020;76(12):1723-30.
271. Al Dweik R, Stacey D, Kohen D, Yaya S. Factors affecting patient reporting of adverse drug reactions: a systematic review. *British Journal of Clinical Pharmacology*. 2017;83(4):875-83.
272. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *International Journal of Social Research Methodology*. 2005;8(1):19-32.
273. Tricco AC, Lillie E, Zarin W, O'Brien K, Colquhoun H, Kastner M, et al. A scoping review on the conduct and reporting of scoping reviews. *BMC Medical Research Methodology*. 2016;16:15.
274. Patel S, Desai C, Dikshit R, Patel P. An impact of educational interventions on reporting of adverse drug reactions. *International Journal of Pharmaceutics*. 2015;5(2):485-92.

275. Darnis D, Mahé J, Vrignaud B, Guen CG-L, Veyrac G, Jolliet P. Adverse drug reactions in pediatric emergency medicine. *Annals of Pharmacotherapy*. 2015;49(12):1298-304.
276. Srikanth S, Adepu R. Evaluation Of Structured Educational Intervention To Community Pharmacists Towards Adverse Drug Reaction Reporting And Monitoring In South Indian District. *Value in Health*. 2017;20(9):A688.
277. Anton C, Dussaye A, Badyal K, Ferner R. Influencing Adverse Drug Reaction Reporting In Primary Care. *Drug Safety*. 2017;40(10):997-8.
278. Srikanth M, Adepu R. Assessment of Impact of Structured Educational Intervention on Adverse Drug Reaction Reporting Behaviour of Community Pharmacists in South India. *Pharmacoepidemiology and Drug Safety*. 2016;25:417.
279. Galicia-Quintanar C, Reyes-Garcia J, Fernandez del Vale-Laisequilla C. Prospective Longitudinal Descriptive Study to Evaluate the Impact of Involves Physician on Training Pharmacovigilance Activities in the Report of AE. *Drug Safety*. 2013;36(9):930.-
280. Marquez S, Herdeiro M, Ribeiro-Vaz I. An Educational Intervention To Improve Nurses Reporting of Adverse Drug Reactions. *Clinical Therapeutics*. 2015;37(8):e57.
281. Herdeiro MT, Polonia J, Gestal-Otero JJ, Figueiras A. Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. *Drug Safety*. 2008;31(4):335-44.

282. Gerritsen R, Faddegon H, Dijkers F, van Grootheest K, van Puijenbroek E. Effectiveness of pharmacovigilance training of general practitioners : a retrospective cohort study in the Netherlands comparing two methods. *Drug Safety*. 2011;34(9):755-62.
283. Ejekam CS, Chuka-Ebene VO, Oreagba IA, Olayemi S, Adewumi A. An educational intervention to improve the knowledge and practice of pharmacovigilance among healthcare professionals in private hospitals in Lagos state, Nigeria. *Pharmacoepidemiology and Drug Safety*. 2015;24:162-3.
284. Johansson M-L, Brunlöf G, Edward C, Wallerstedt SM. Effects of e-mails containing ADR information and a current case report on ADR reporting rate and quality of reports. *European Journal of Clinical Pharmacology*. 2009;65(5):511-4.
285. Johansson M-L, Hägg S, Wallerstedt SM. Impact of information letters on the reporting rate of adverse drug reactions and the quality of the reports : a randomized controlled study. *BMC Clin Pharmacol*. 2011;11(1):14.
286. Backstrom M, Mjorndal T. A small economic inducement to stimulate increased reporting of adverse drug reactions--a way of dealing with an old problem? *European Journal of Clinical Pharmacology*. 2006;62(5):381-5.
287. Desai C, Patel S, Patel P, Dikshit R. effect Of Educational Interventions On Reporting Of Adverse Drug Reactions By Prescribers. *Basic & Clinical Pharmacology & Toxicology* 2014;115:68.

288. Gony M, Badie K, Sommet A, Jacquot J, Baudrin D, Gauthier P, et al. Improving adverse drug reaction reporting in hospitals: results of the French Pharmacovigilance in Midi-Pyrenees region (PharmacoMIP) network 2-year pilot study. *Drug Safety*. 2010;33(5):409-16.
289. Jacquot J, Gony M, Baudrin D, Chastel X, Montastruc JL, Bagheri H. [Could we improve notification of adverse drugs reactions in hospital? Assessment of 5 years of network PharmacoMIP's activities]. *Therapie*. 2012;67(3):231-6.
290. Durrieu G, Jacquot J, Baudrin D, Mege M, Rousseau V, Bagheri H, et al. [Improving adverse drug reaction reporting by general practitioners through clinical research assistants visits]. *Therapie*. 2017;72(3):351-5.
291. Bismuth M, Durrieu G, Mege M, Jacquot J, Rousseau V, Oustric S, et al. Improving adverse drug reaction reporting by general practitioners in south-west of France. *Drug Safety*. 2015;38(10):1011-2.
292. Jacquot J, Durrieu G, Mege M, Rousseau V, Bagheri H, Bondon-Guitton E, et al. Improving adverse drug reaction reporting by general practitioners in south-west of France. *Fundamental & Clinical Pharmacology*. 2016;30(Suppl. 1):63.
293. Gony M, Sommet A, Jacquot I, Baudrin D, Gauthier P, Montastruc J, et al. How to improve reporting of Adverse Drug Reactions from hospitals: the results of the pilot study of the French PharmacoMIP over a three-year period. *Fundamental & Clinical Pharmacology*. 2010;24(Suppl. 1):81-2.

294. Sullivan KM, Spooner LM. Adverse-drug-reaction reporting by pharmacy students in a teaching hospital. *American Journal of Health-System Pharmacy*. 2008;65(12):1177-9.
295. Grilli D, Gelsomino F, Massari F, Angelelli B, Tognetto M, Restuccia S, et al. The impact of the clinical pharmacist (cp) in reporting suspected adverse drug reactions (adrs): the experience of the Medical Oncology Unit at the S. orsola-malpighi University Hospital. *Annals of Oncology*. 2016;27(suppl\_4):iv115.
296. Baek HJ, Cho YS, Kim KS, Lee J, Kang HR, Suh DI. Multidisciplinary approach to improve spontaneous ADR reporting in the pediatric outpatient setting: a single-institute experience in Korea. *SpringerPlus*. 2016;5(1):1435.
297. He W, Yao D, Hu Y, Dai H. Analysis of a pharmacist-led adverse drug event management model for pharmacovigilance in an academic medical center hospital in China. *Ther Clin Risk Manag*. 2018;14:2139-47.
298. Galfrascoli E, Magni E, Panciroli C, Bonfatti C, Cerveri G, Boschiero AM, et al. Improving pharmacovigilance in psychiatry. *European Journal of Hospital Pharmacy*. 2012;19(2):110.
- .299 Mahe J, Darnis D, Vrignaud B, Gras-Le-Guen C, Veyrac G, Jolliet P. Pharmacovigilance center and pediatric emergency unit: Closer collaboration necessary. *Fundamental & Clinical Pharmacology*. 2015;29(Suppl. 1):51.

300. Sánchez I, Amador C, Plaza JC, Correa G, Amador R. Impacto clínico de un sistema de farmacovigilancia activa realizado por un farmacéutico en el reporte y subnotificación de reacciones adversas a medicamentos. *Revista Médica de Chile*. 2014;142(8):998-1005.
301. Schlienger RG, Luscher TF, Schoenenberger RA, Haefeli WE. Academic detailing improves identification and reporting of adverse drug events. *Pharmacy World & Science*. 1999;21(3):110-5.
302. Montastruc F, Bagheri H, Lacroix I, Damase-Michel C, Chebane L, Rousseau V, et al. Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP((R)): A Comparison with Classical Methods of Reporting. *Drug Safety*. 2018;41(5):511-4.
303. Ruellan A, Allavena C, Jovelin T, Billaud E, Bonnet B, Feuillebois N, et al. increase in the rate of spontaneous adverse drug reaction notification and improvement of pharmacologic quality analysis in a department of infectious diseases using an electronic medical record: Nadis®: 05-01. *Fundamental & Clinical Pharmacology*. 2013;27(Suppl. 1):11-2.
304. Guédat M-G, Gouraud A, Ramiah T, Demazière J, Delanoy B, Vial T, et al. Pharmacie clinique et pharmacovigilance a l'hôpital : bilan et perspectives après 9 ans d'expérience. *Thérapie*. 2012;67(3):243-50.
305. Lombart A, Dehours E, Durrieu G, Manrique F, Bounes V, Montastruc J. Increased reporting of adverse drug reactions in a hospital emergency department. *Fundamental & Clinical Pharmacology*. 2017;31(Suppl. 1):62-3.



306. Abadie D, Chebane L, Bert M, Durrieu G, Montastruc JL. Online reporting of adverse drug reactions : a study from a French regional pharmacovigilance center. *Therapie*. 2014;69(5):395-400.
307. Taam MA, Herlem E, Roux M, Trenque T. Drug safety 2.0 in a Regional Center of Pharmacovigilance. *Fundamental & Clinical Pharmacology*. 2015;29(Suppl. 1):66.
308. Humbert X, Chrétien B, Sassier M, Coquerel A, Alexandre J, Fedrizzi S. Evaluation of a new pharmacovigilance tool : Simplified online reporting for general practitioners. *Santé Publique*. 2018;30(2):225-32.
309. Pochard L, Hauviller L, Cuzin L, Eyvrard F, Sommet A, Montastruc J-L, et al. Use of Nadis (®) software to improve adverse drug reaction reporting of antiretroviral drugs : experience in south west of France (midi-pyrénées). *Therapie*. 2014;69(2):149-55.
310. Mostella J, Throgmorton P, Cramer R. A systematic approach to improve reporting and analysis of adverse drug events. *Pharmacotherapy*. 2005;25(3):476.-
311. Lee SB, Schepers GP, Goldberg KL. Electronic adverse-drug-reaction-reporting program. *American Journal of Health-System Pharmacy*. 2004;61(12):1230, 2-3.
312. Lowry JA, Sullin AK, Sandritter TL, Leeder JS. Adverse drug reaction surveillance in a pediatric hospital. *Journal of Veterinary Pharmacology and Therapeutics*. 2013;93(SUPPL. 1):S58.
313. Salcedo De Diego I, Serrano Gallardo P, Ruiz Antorán B, De Andrés Gimeno B, Revuelta Zamorano M, Avendaño Solá C. Impact of a multicomponent intervention on registered nurses to

increase reporting of adverse drug reactions and medication errors. *Clinical Therapeutics*. 2015;37(8):e153.

314. Ortega A, Aguinagalde A, Lacasa C, Aquerreta I, Fernández-Benítez M, Fernández LM. Efficacy of an adverse drug reaction electronic reporting system integrated into a hospital information system. *Annals of Pharmacotherapy*. 2008;42(10):1491-6.

315. Inés RV, Cristina S, Altamiro C-P, Ricardo C-C. Using informatics to promote spontaneous adverse drug reaction reporting. *European Journal of Integrative Medicine*. 2012;4s:194.

316. Park CS, Kim TB, Kim SL, Kim JY, Yang KA, Bae YJ, et al. The use of an electronic medical record system for mandatory reporting of drug hypersensitivity reactions has been shown to improve the management of patients in the university hospital in Korea. *Pharmacoepidemiology and Drug Safety*. 2008;17(9):919-25.

317. Garza-Ocanas L, Perez-Rdz A, Perez-Garza A, Gonzalez-Nieto C, Escobedo-Pena J, Perez-Rodríguez E. ADRS and medication errors surveillance after the implementation of an electronic report system. *Drug Safety*. 2017;40(10):1013-4.

318. Fracchiolla NS, Artuso S, Cortelezzi A, Pelizzari AM, Tozzi P, Bonfichi M, et al. FarmaREL : An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patients. *Hematological Oncology*. 2018;36(1):299-306.

319. Chen PC, Lei TH, Tseng CT, Chen LC. Establishment of an information platform increases spontaneous reporting of adverse drug reactions. *International Journal of Clinical Pharmacy*. 2018;40(1):254.
320. Chen CJ, Cheng CF, Lin HY, Hung SP, Chen WC, Lin MS. A comprehensive 4-year survey of adverse drug reactions using a network-based hospital system. *Journal of Clinical Pharmacy and Therapeutics*. 2012;37(6):647-51.
321. Al-Braik F, Al Ghufli M, Saad R, Hasan M. Adverse Drug Reactions Monitoring in Public Hospitals Using Patient Safety Network System. *Drug Safety*. 2016;39(10):1005-6.
322. Humbert X, Alexandre J, Sassier M, Coquerel A, Fedrizzi S. Simplified pharmacovigilance reporting in primary care: one year results. *Fundamental & Clinical Pharmacology*. 2017;31(Suppl. 1):32.-
323. Cereza G, Agusti A, Pedros C, Vallano A, Aguilera C, Danes I, et al. Effect of an intervention on the features of adverse drug reactions spontaneously reported in a hospital. *European Journal of Clinical Pharmacology*. 2010;66(9):937-45.
324. Capucho H, Reis L, Siqueira S, Pereira L. Strategies Impact to Increase the Reporting of Pharmacovigilance in a Brazilian University Hospital. *Drug Safety*. 2008;31(10):885.-
325. Bracchi RC, Houghton J, Woods FJ, Thomas S, Smail SA, Routledge PA. A distance-learning programme in pharmacovigilance linked to educational credits is associated with improved

reporting of suspected adverse drug reactions via the UK yellow card scheme. *British Journal of Clinical Pharmacology*. 2005;60(2):221-3.

326. Colodny L, Spillane J. Toward Increased Reporting of Adverse Drug Reactions. *Hospital Pharmacy*. 1999;34(10):1179-85.

327. Khairnar A, Gade PR. Interventional Improvement in Hospital Based Intensive Monitoring of Adverse Event. *International Journal of Pharmaceutical Sciences and Drug Research*. 2011;4(9):1443-8.

328. Al-Tajir GK, Kelly WN. Epidemiology, comparative methods of detection, and preventability of adverse drug events. *Annals of Pharmacotherapy*. 2005;39(7-8):1169-74.

329. Rouillet-Renoleau F, Berdot S, Bouvet A, Le Beller C, Sabatier B, Capron L, et al. Pharmacist's intervention to improve physician reporting of adverse drug reactions in a French University hospital. *International Journal of Clinical Pharmacy*. 2012;34(1):226-7.

330. Palleria C, Iannone L, Leporini C, Citraro R, Manti A, Caminiti M, et al. Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP). *PLOS One*. 2018;13(10):e0205134.

331. Abbas A, Green C. The Chester Experience-The impact of an intervention to improve Adverse Drug Reactions reporting in a district general hospital. *Drug Safety*. 2017;40(10):1032.-

332. Ratz Y, Shafir I, Berkovitch S, Sharristh M, Jacoby M, Kozer E, et al. The importance of the pharmacist in reporting adverse drug reactions in the emergency department. *The Journal of Clinical Pharmacology*. 2010;50(10):1217-21.
333. Garza-Ocañas L, Perez-Rodríguez E, González-Nieto C, Guzmán-López S. Pharmacovigilance at a University Hospital: Strategies Developed for Increasing Adverse Drug Reactions and Medication Errors Reporting. *Drug Safety*. 2014;37(10):848-9.
334. Garza-Ocanas L, Escobedo Pena J, Gonzalez-Nieto C, Perez-Rodriguez E, Guzman-Lopez S, Aponte E, et al. Underreporting Adverse Drug Reactions (ADR) and Medication Errors (ME): a Problem in Hospital Pharmacovigilance. *Drug Safety*. 2015;38(10):985.-
335. Pagotto C, Varallo F, Mastroianni P. Impact of educational interventions on adverse drug events reporting. *International Journal of Technology Assessment in Health Care*. 2013;29(4):410-7.
336. Hussain SA, Abbas AN, Habeeb S-ZA, Abd-Ali AK, Abdulrahman ZS. Healthcare personnel's experience of reporting adverse drug reactions in Baghdad city: cross-sectional study. *International Journal of Clinical Pharmacy*. 2019;41(5):1307-13.
337. Nisa ZU, Zafar A, Sher F. Assessment of knowledge, attitude and practice of adverse drug reaction reporting among healthcare professionals in secondary and tertiary hospitals in the capital of Pakistan. *Saudi Pharmaceutical Journal*. 2018;26(4):453-61.

338. Akel M, Ramia E, Hajj A, Hallit S, Lahoud N, Zaytoun A, et al. Medication Safety Spontaneous Reporting System : The Lebanese Order of Pharmacists Initiative. *Bulletin of Faculty of Pharmacy, Cairo University*. 2019;57(1):66-81.
339. Gonzalez-Gonzalez C, Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Strategies to improve adverse drug reaction reporting : a critical and systematic review. *Drug Safety*. 2013;36(5):317-28.
340. Ribeiro-Vaz I, Santos C, da Costa-Pereira A, Cruz-Correia R. Promoting spontaneous adverse drug reaction reporting in hospitals using a hyperlink to the online reporting form : an ecological study in Portugal. *Drug Safety*. 2012;35(5):387-94.
341. Van Eekeren R, Rolfes L, Koster AS, Magro L, Parthasarathi G, Al Ramimmy H, et al. What future healthcare professionals need to know about pharmacovigilance : introduction of the WHO PV core curriculum for university teaching with focus on clinical aspects. *Drug Safety*. 2018;41(11):1003-11.
342. Arshad A, Noordin MB, Othman R. A synthesis on swot analysis of public sector healthcare knowledge management information systems in Pakistan. *International Journal of Advanced Computer Science and Applications*. 2017;8(8):130-6.
343. von Kodolitsch Y, Bernhardt AM, Robinson PN, Kölbl T, Reichenspurner H, Debus S, et al. Analysis of Strengths, Weaknesses, Opportunities, and Threats as a Tool for Translating Evidence into Individualized Medical Strategies (I-SWOT). *Aorta (Stamford)*. 2015;3(3):98-107.
344. Dal Pan GJ. Ongoing Challenges in Pharmacovigilance. *Drug Safety*. 2014;37(1):1-8.

345. Venkatraman JV. Pharmacovigilance Programme of India : SWOT Analysis. Global Forum. 2017;9(1):22-6.
346. Peters T, Soanes N, Abbas M, Ahmad J, Delumeau J-C, Herrero-Martinez E, et al. Effective Pharmacovigilance System Development: EFPIA-IPVG Consensus Recommendations. Drug Safety. 2020.
347. Akici A, Oktay S. Rational pharmacotherapy and pharmacovigilance. Current Drug Safety. 2007;2(1):65-9.
348. Tang A. Evaluating the evidence base in pharmacovigilance decision making. England: University of Portsmouth; 2010.
349. Zhang L, Wong LYL, He Y, Wong ICK. Pharmacovigilance in China : Current Situation, Successes and Challenges. Drug Safety. 2014;37(10):765-70.
350. Ampadu HH, Hoekman J, de Bruin ML, Pal SN, Olsson S, Sartori D, et al. Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World : Analyses of Spontaneous Reports in VigiBase®. Drug Safety. 2016;39(4):335-45.
351. Piccinni C, Poluzzi E, Orsini M, Bergamaschi S, editors. PV-OWL — Pharmacovigilance surveillance through semantic web-based platform for continuous and integrated monitoring of drug-related adverse effects in open data sources and social media. 2017 IEEE 3rd International

Forum on Research and Technologies for Society and Industry (RTSI); 2017 11-13 Sept. 2017; Modena, Italy.

352. Akinola S, da Silveira CG, Corbin S, Lavallé e M, Thibault M, Gonella J, et al. Using Data from the Canadian Post-marketing Spontaneous Pharmacovigilance System for Drug Safety Research : A Feasibility Study. *Pharmaceutical Medicine*. 2020;34(4):263-9.

353. Li X, Li H, Deng J, Zhu F, Liu Y, Chen W, et al. Active pharmacovigilance in China : recent development and future perspectives. *European Journal of Clinical Pharmacology*. 2018;74(7):863-71.

354. Sonawane KB, Cheng N, Hansen RA. Serious Adverse Drug Events Reported to the FDA : Analysis of the FDA Adverse Event Reporting System 2006-2014 Database. *Journal of managed care & specialty pharmacy*. 2018;24(7):682-90.

355. Gargi Tarafdar MAAAM. Trends in the Reporting of Adverse Drug Reactions : A Global Review of Literature. *Indian Journal of Public Health Research & Development*. 2019;10(12):828-32.

356. Patrignani A, Palmieri G, Ciampani N, Moretti V, Mariani A, Racca L. [Under-reporting of adverse drug reactions, a problem that also involves medicines subject to additional monitoring. Preliminary data from a single-center experience on novel oral anticoagulants]. *Giornale italiano di cardiologia*. 2018;19(1):54-61.



357. McMaster C, Liew D, Keith C, Aminian P, Frauman A. A Machine-Learning Algorithm to Optimise Automated Adverse Drug Reaction Detection from Clinical Coding. *Drug Safety*. 2019;42(6):721-5.
358. Zhu J, Stuver SO, Epstein AM, Schneider EC, Weissman JS, Weingart SN. Can We Rely on Patients' Reports of Adverse Events? *Medical Care*. 2011;49(10):948-55.
359. Rolfes L, van Hunsel F, van der Linden L, Taxis K, van Puijenbroek E. The Quality of Clinical Information in Adverse Drug Reaction Reports by Patients and Healthcare Professionals : A Retrospective Comparative Analysis. *Drug Safety*. 2017;40(7):607-14.
360. Matos C, Weits G, van Hunsel F. The Role of European Patient Organizations in Pharmacovigilance. *Drug Safety*. 2019;42(4):547-57.
361. Aboul Fotouh AM, Ismail NA, Ez Elarab HS, Wassif GO. Assessment of patient safety culture among health-care providers at a teaching hospital in Cairo, Egypt. *Eastern Mediterranean Health Journal*. 2012;18(4):372-7.
362. Norén GN, Caster O, Juhlin K, Lindquist M. Zoo or Savannah? Choice of Training Ground for Evidence-Based Pharmacovigilance. *Drug Safety*. 2014;37(9):655-9.
363. Asseray N, Ballereau F, Trombert-Paviot B, Bouget J, Foucher N, Renaud B, et al. Frequency and severity of adverse drug reactions due to self-medication: a cross-sectional multicentre survey in emergency departments. *Drug Safety*. 2013;36(12):1159-68.

364. Nzolo D, Kuemmerle A, Lula Y, Ntamabyaliro N, Engo A, Mvete B, et al. Development of a pharmacovigilance system in a resource-limited country: the experience of the Democratic Republic of Congo. *Ther Adv Drug Saf.* 2019;10:2042098619864853 .
365. Van Wijngaarden JD, Scholten GR, van Wijk KP. Strategic analysis for health care organizations: the suitability of the SWOT-analysis. *The International Journal of Health Planning and Management.* 2012;27(1):34-49.
366. Thajer A, Sommersguter-Reichmann M, Löffler-Stastka H. Implementing a Clinical Research Department to Support Pediatric Studies: A SWOT Analysis. *International Journal of Environmental Research and Public Health.* 2020;17(17):6211 .
367. Tavares AI. Portuguese Health System, an Overview and a SWOT Review. *The Open Public Health Journal.* 2016;9(1).



بسمه تعالی

تاریخ ۹۷/۲/۲۶

صور تجلسه دفاع از پایان نامه

شماره ۱۵۱۸۷/۱۲۷

دانشگاه علوم پزشکی کرمان

مدیریت تحصیلات تکمیلی دانشگاه

جلسه دفاعیه پایان نامه تحصیلی خانم ملاحظت خلیلی کیسیمی دانشجوی دکتری تخصصی (Ph.D) رشته اپیدمیولوژی دانشکده بهداشت دانشگاه علوم پزشکی کرمان تحت عنوان "تحلیل نظام فارماکوپولیزیلانس ایران" در ساعت ۷:۳۰ روز دو شنبه مورخ ۹۹/۱۲/۱۱ با حضور اعضای محترم هیات داوران به شرح ذیل:

امضا	نام و نام خانوادگی	سمت
	آقای دکتر علی اکبر حقدوست آقای دکتر حمید شریفی	الف: استاد(ان) راهنما
	خانم دکتر بیبا مسگریور خانم دکتر مهرناز خیراندیش	ب: استاد(ان) مشاور
	خانم دکتر فرزانه ذوالعلی	ج: عضو هیات داوران (داخلی)
	خانم دکتر آرمیتا شاه اسماعیلی	ج: عضو هیات داوران (داخلی)
	آقای دکتر اکبر فتوحی	د: عضو هیات داوران (خارجی)
	خانم دکتر سنا عیب پوش	د: عضو هیات داوران (خارجی)
	آقای دکتر حمیدرضا توحیدی نیک	ه: نماینده تحصیلات تکمیلی

تشکیل گردید و ضمن ارزیابی به شرح پیوست با درجه عالی و نمره ۱۹،۹۸ نمره و نمره مورد تأیید قرار گرفت.

مهر و امضاء معاون آموزشی

۱۴-۱-۰۰

